<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">36389</article-id><article-id pub-id-type="doi">10.7554/eLife.36389</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>The cJUN NH<sub>2</sub>-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-108585"><name><surname>Girnius</surname><given-names>Nomeda</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7267-5950</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57710"><name><surname>Edwards</surname><given-names>Yvonne JK</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108588"><name><surname>Garlick</surname><given-names>David S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1072"><name><surname>Davis</surname><given-names>Roger J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0130-1652</contrib-id><email>roger.davis@umassmed.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Program in Molecular Medicine</institution><institution>University of Massachusetts Medical School</institution><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Histo-Scientific Research Laboratories</institution><addr-line><named-content content-type="city">Mount Jackson</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Howard Hughes Medical Institute, University of Massachusetts Medical School</institution><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-44836"><name><surname>Frame</surname><given-names>Margaret C</given-names></name><role>Reviewing Editor</role><aff id="aff4"><institution>University of Edinburgh</institution><country>United Kingdom</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>01</day><month>06</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e36389</elocation-id><history><date date-type="received" iso-8601-date="2018-03-04"><day>04</day><month>03</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-05-09"><day>09</day><month>05</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Girnius et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Girnius et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-36389-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.36389.001</object-id><p>Breast cancer is the most commonly diagnosed malignancy in women. Analysis of breast cancer genomic DNA indicates frequent <italic>loss-of-function</italic> mutations in components of the cJUN NH<sub>2</sub>-terminal kinase (JNK) signaling pathway. Since JNK signaling can promote cell proliferation by activating the AP1 transcription factor, this apparent association of reduced JNK signaling with tumor development was unexpected. We examined the effect of JNK deficiency in the murine breast epithelium. Loss of JNK signaling caused genomic instability and the development of breast cancer. Moreover, JNK deficiency caused widespread early neoplasia and rapid tumor formation in a murine model of breast cancer. This tumor suppressive function was not mediated by a role of JNK in the growth of established tumors, but by a requirement of JNK to prevent tumor initiation. Together, these data identify JNK pathway defects as ‘driver’ mutations that promote genome instability and tumor initiation.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.36389.002</object-id><title>eLife digest</title><p>As cells in our body grow and divide, their DNA can experience changes or damage. Most of these ‘mutations’ are harmless, or quickly fixed by the body. Yet, sometimes a mutation can trigger a chain of genetic events that drives the cells to multiply uncontrollably, which leads to tumors. Identifying these ‘driver mutations’ is complex, but key to understanding how cancers start and can be fought.</p><p>Breast cancer is the most common type of cancer diagnosed in women worldwide. Large studies have focused on sequencing the DNA of cancerous breast cells to try to identify the mutations that started the cancer. Results show that, in these cells, a biological mechanism called the JNK signaling pathway is often inactivated because mutations affect the molecules that take part in this process. Like a chain reaction, the proteins of the JNK pathway act on each other until the last one, called JNK, gets switched on. This protein then goes on to participate in a number of cellular processes such as DNA repair. Is it possible that mutations in this pathway actually drive cancer, and if so, how?</p><p>Girnius et al. addressed these questions by inactivating the JNK pathway in the breast cells of mice. Over the next year and a half, the JNK-deficient animals were more likely to get breast cancer than normal mice. Further experiments showed that, in breast cells, the JNK protein prevented tumors from appearing. However, once the tumors were present, it was less effective at stopping them from growing. The DNA of the breast cancer cells with no JNK protein also contained more genetic changes and mistakes. This suggests that the JNK signaling pathway helps to keep the genetic information ‘healthy’. This may be because, normally, the JNK protein activates processes that fix DNA mutations. Taken together, the results presented by Girnius et al. show that genetic changes which inactivate the JNK pathway can drive the development of breast cancer.</p><p>Certain anti-cancer drugs kill cancerous cells by damaging their DNA. Breast tumor cells with inactive JNK pathways are less able to repair their genetic information, and so these drugs could potentially work well on them. Future experiments will be needed to test this hypothesis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>stress-activated MAPK</kwd><kwd>JNK</kwd><kwd>breast cancer</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Investigator</award-id><principal-award-recipient><name><surname>Davis</surname><given-names>Roger J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK107220</award-id><principal-award-recipient><name><surname>Davis</surname><given-names>Roger J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK112698</award-id><principal-award-recipient><name><surname>Davis</surname><given-names>Roger J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mutational inactivation of the JNK signaling pathway causes genomic instability and breast cancer development.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Breast cancer is the most frequently diagnosed tumor in women (<xref ref-type="bibr" rid="bib56">Siegel et al., 2015</xref>). The etiology of breast cancer has been studied in detail, but the causes of breast cancer remain incompletely understood. Nevertheless, it is established that familial breast cancers result from germ-line mutations that increase the risk of cancer development (<xref ref-type="bibr" rid="bib1">Afghahi and Kurian, 2017</xref>). Examples of inherited mutations that can cause breast cancer predisposition include <italic>ATM</italic>, <italic>BRCA1/2</italic>, <italic>CDH1</italic>, <italic>CHEK2</italic>, <italic>NBN</italic>, and <italic>TP53</italic>. Moreover, sporadic mutation of these and other genes promote the development of non-familial breast cancer (<xref ref-type="bibr" rid="bib27">Hanahan and Weinberg, 2011</xref>). Changes in the tumor genome are therefore important for breast cancer development (<xref ref-type="bibr" rid="bib27">Hanahan and Weinberg, 2011</xref>).</p><p>Recent advances in breast cancer genome analysis have led to significant progress towards the identification of sporadic mutations in breast cancer (<xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib14">Ciriello et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Ellis et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Kan et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Nik-Zainal et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Shah et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Stephens et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Wang et al., 2014</xref>). These genetic changes include ‘driver’ mutations that promote tumor development and ‘passenger’ mutations that do not functionally contribute to the tumor phenotype. Genes mutated in familial cancer syndromes constitute a prime example of ‘driver’ mutations that can contribute to cancer development. The presence of ‘passenger’ mutations complicates the analysis of cancer genomes for the development of targeted tumor therapy. For example, some ‘driver’ mutations cause genetic instability (e.g. <italic>ATM</italic>, <italic>BRCA1/2</italic>, <italic>CHEK2</italic>, <italic>NBN</italic> and <italic>TP53</italic>) that can result in the accumulation of additional mutations in developing tumors.</p><p>Computational methods have been employed to distinguish ‘driver’ and ‘passenger’ mutations based on mutation frequency (<xref ref-type="bibr" rid="bib46">Parmigiani et al., 2009</xref>), gene function in pathways (<xref ref-type="bibr" rid="bib38">Lin et al., 2007</xref>; <xref ref-type="bibr" rid="bib73">Wendl et al., 2011</xref>), level of gene expression (<xref ref-type="bibr" rid="bib4">Berger et al., 2016</xref>) and predictions based on gene function (<xref ref-type="bibr" rid="bib9">Carter et al., 2009</xref>; <xref ref-type="bibr" rid="bib29">Kaminker et al., 2007</xref>; <xref ref-type="bibr" rid="bib78">Youn and Simon, 2011</xref>) and protein interactions (<xref ref-type="bibr" rid="bib2">Babaei et al., 2013</xref>; <xref ref-type="bibr" rid="bib12">Cerami et al., 2010</xref>). These computational approaches to identify ‘driver’ mutations have been complemented by functional siRNA screens on breast tumor cell lines (<xref ref-type="bibr" rid="bib40">Marcotte et al., 2016</xref>; <xref ref-type="bibr" rid="bib51">Sanchez-Garcia et al., 2014</xref>). Collectively, these approaches have led to the identification of ‘driver’ mutations in human cancer, but it is likely that many more ‘driver’ mutations remain to be discovered (<xref ref-type="bibr" rid="bib19">Garraway and Lander, 2013</xref>).</p><p>Examples of ‘driver’ mutations in breast cancer include the <italic>TP53</italic>, <italic>PIK3CA</italic>, and <italic>PTEN</italic> genes. Mutational inactivation of <italic>PTEN</italic> or activation of <italic>PI3K</italic> increases AKT/mTOR signaling that promotes growth, proliferation, and survival (<xref ref-type="bibr" rid="bib79">Yuan and Cantley, 2008</xref>), while mutation of <italic>TP53</italic> promotes cell survival and proliferation (<xref ref-type="bibr" rid="bib68">Vousden and Prives, 2009</xref>). The appreciation of the importance of these pathways in cancer has spurred research into potential therapies (<xref ref-type="bibr" rid="bib68">Vousden and Prives, 2009</xref>; <xref ref-type="bibr" rid="bib79">Yuan and Cantley, 2008</xref>). These well-established ‘driver’ mutations contribute to the etiology of breast cancer. In contrast, the role of some other highly mutated genes in breast cancer is unclear.</p><p>One frequently mutated pathway in breast cancer is the cJUN NH<sub>2</sub>-terminal kinase (JNK) pathway (<xref ref-type="bibr" rid="bib19">Garraway and Lander, 2013</xref>). The JNK pathway is a three-tiered cascade that includes a MAP kinase kinase kinase (MAP3K) that phosphorylates and activates MAP kinase kinases (MAP2K) that, in turn, phosphorylate and activate JNK (<xref ref-type="bibr" rid="bib16">Davis, 2000</xref>). This pathway requires two MAP2K isoforms that co-operate to activate JNK by phosphorylation on tyrosine (by MAP2K4) and threonine (by MAP2K7) (<xref ref-type="bibr" rid="bib62">Tournier et al., 2001</xref>). The sequencing of breast tumor genomic DNA has revealed mutations in genes that encode members of this pathway, including <italic>MAP3K1</italic>, <italic>MAP2K4</italic>, and <italic>MAP2K7</italic> (<xref ref-type="bibr" rid="bib3">Banerji et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib14">Ciriello et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Ellis et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Kan et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Nik-Zainal et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Shah et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Stephens et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Wang et al., 2014</xref>). The genetic changes include frequent deletion of the gene locus and mutations that cause protein truncation and loss of protein kinase activity. This analysis suggests that breast cancer is associated with loss of JNK signaling. Indeed, since AKT phosphorylates and inactivates MAP2K4 (<xref ref-type="bibr" rid="bib45">Park et al., 2002</xref>), breast cancer ‘driver’ mutations that activate AKT (e.g. <italic>PTEN</italic> and <italic>PI3K</italic>) also cause loss of JNK signaling. The JNK signaling pathway may therefore be suppressed in many breast cancers.</p><p>The association of breast cancer with reduced JNK signaling represents a correlation. What is the significance of <italic>loss-of-function</italic> JNK pathway mutations? Are these ‘driver’ or ‘passenger’ mutations? The purpose of this study was to test the role of JNK signaling in breast cancer development. Since JNK signaling causes AP1 transcription factor activation, we anticipated that JNK may act to promote tumor growth. In contrast, we found that loss of JNK signaling in mammary epithelial cells caused breast cancer. Furthermore, JNK deficiency accelerated tumor formation in a murine model of breast cancer. These effects of JNK deficiency to promote tumor development were associated with widespread presence of early neoplasia and genomic instability. We show that JNK plays a key role in the initiation of tumor development. Thus, the frequent <italic>loss-of-function</italic> JNK pathway mutations in breast tumors represent ‘driver’ mutations that promote breast cancer development.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Disruption of JNK signaling causes breast cancer development</title><p><italic>Loss-of-function</italic> mutations in the JNK signaling pathway (e.g. <italic>MAP3K1</italic>, <italic>MAP2K4</italic>, and <italic>MAP2K7</italic>) are implicated in the etiology of breast cancer (<xref ref-type="bibr" rid="bib3">Banerji et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib14">Ciriello et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Ellis et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Kan et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Nik-Zainal et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Shah et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Stephens et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Wang et al., 2014</xref>). These potential ‘driver’ mutations in breast cancer cause disruption of JNK signaling. To test whether JNK pathway disruption influences breast cancer development, we examined the effect of JNK-deficiency in the mammary epithelium. The JNK1 (encoded by <italic>Mapk8</italic>) and JNK2 (encoded by <italic>Mapk9</italic>) isoforms exhibit partially redundant functions (<xref ref-type="bibr" rid="bib16">Davis, 2000</xref>). We therefore examined compound JNK deficiency in the mammary epithelium using Control (ME<sup>CRE</sup>: <italic>Wap-Cre<sup>+/- </sup>Mapk8<sup>+/+ </sup>Mapk9<sup>+/+</sup></italic> and ME<sup>WT</sup>: <italic>Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic>) mice and JNK-deficient (ME<sup>KO</sup>: <italic>Wap-Cre<sup>+/- </sup>Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic>) mice. Lactation induces <italic>Wap-Cre</italic> expression (<xref ref-type="bibr" rid="bib69">Wagner et al., 1997</xref>). Studies using <italic>Rosa26<sup>mTmG+/-</sup></italic> female reporter mice demonstrated <italic>Cre</italic>-mediated recombination in cytokeratin 8 (CK8) positive luminal epithelial cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), but not in cytokeratin 5 (CK5) positive myoepithelial cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.36389.003</object-id><label>Figure 1.</label><caption><title>JNK deficiency in mammary epithelial cells causes genomic instability and tumor formation.</title><p>(<bold>A, B</bold>) Mammary gland tissue sections were prepared from parous <italic>Wap-Cre<sup>+/- </sup>Rosa26<sup>mTmG+/-</sup></italic> female mice (n = 6) on day 21 post-weaning. These sections were stained with antibodies to cytokeratin 8 (CK8, red (<bold>A</bold>)) or cytokeratin 5 (CK5, red (<bold>B</bold>)), and GFP (green), and counterstained with DAPI (blue). Representative images are presented (<italic>upper panel</italic>, scale bar = 48 µm). Boxed area was magnified (<italic>lower panel</italic>, scale bar = 24 µm). (<bold>C</bold>) Summary of the study cohort showing the total number of <italic>Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic> (ME<sup>WT</sup>) and <italic>Wap-Cre<sup>+/- </sup>Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic> (ME<sup>KO</sup>) mice examined, the number of mice exhibiting mammary intraepithelial neoplasia (MIN) or tumors (*p=0.037, **p=0.0084; Fisher’s Exact Test) (<italic>left panel</italic>). The type of carcinoma is presented (<italic>right panel</italic>). (<bold>D</bold>) Extracts prepared from ME<sup>KO</sup> and <italic>Wap-Cre<sup>+/- </sup>Trp53<sup>LoxP/LoxP</sup></italic> (JNK<sup>WT</sup>) tumor cells were subjected to immunoblot analysis using antibodies to JNK and α-Tubulin. The ME<sup>KO</sup> tumors examined were representative of adenocarcinoma (#1), tumors with characteristics of both adenocarcinoma and adenosquamous carcinoma (#2), and adenosquamous carcinoma (#3). (<bold>E, F</bold>) Representative hematoxylin and eosin (H and E) -stained sections of adenosquamous carcinomas (<bold>E</bold>) and adenocarcinomas (<bold>F</bold>) from ME<sup>KO</sup> female mice are presented. Scale bar = 100 µm. (<bold>G</bold>) Exome sequencing was performed on ME<sup>KO</sup> tumor cell lines (n = 3). Mammary tissue from a virgin female of the same genotype (<italic>Wap-Cre<sup>+/- </sup>Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic>) was used as the reference genome. Circos plots showing copy number variations (CNVs) in ME<sup>KO</sup> tumor cells are presented. The outermost ring shows chromosome ideograms. The next track indicates high (red) and moderate (yellow) impact single nucleotide variants and indels marked by rectangles and triangles, respectively. The innermost track shows chromosome amplifications and deletions, with red and blue lines indicating chromosomal fragments present at log<sub>2</sub>(ratio tumor/normal)&gt;0.2 or log<sub>2</sub>(ratio tumor/normal)&lt;−0.2, respectively.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.006</object-id><label>Figure 1—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig1">Figure 1C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><object-id pub-id-type="doi">10.7554/eLife.36389.007</object-id><label>Figure 1—source data 2.</label><caption><title>Source image data for <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</title><p>Whole immunoblot scans are presented and the region used to construct <xref ref-type="fig" rid="fig1">Figure 1D</xref> is outlined.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-36389-fig1-data2-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig1-v1"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Expression of estrogen and progesterone receptors in breast tumors caused by JNK deficiency in the mammary epithelium.</title><p>(<bold>A, B</bold>) Representative adenocarcinoma (<italic>upper panel</italic>) and adenosquamous carcinoma (<italic>lower panel</italic>) sections stained for progesterone receptor (PR), estrogen receptor (ER) (Scale bar = 100 µm), and cytokeratin 8 (CK8, green) and cytokeratin 5 (CK5, red) (Scale bar = 50 µm) are presented. Immunofluorescent stains were counterstained with DAPI (<italic>left panels</italic>), and peroxidase-based staining was counterstained with hematoxylin (<italic>center</italic> and <italic>right panels</italic>) (<bold>A</bold>). Adenocarcinomas and adenosquamous carcinomas were scored for hormone receptor staining (<bold>B</bold>).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig1-figsupp1-v1"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Summary of exome sequence data.</title><p>(<bold>A</bold>) Nomenclature Key: JNK<sup>WT</sup> (tumors from parous <italic>Wap-Cre<sup>+/- </sup>Mapk8<sup>+/+ </sup>Mapk9<sup>+/+ </sup>Trp53</italic><sup><italic>LoxP/LoxP</italic></sup> mice); JNK<sup>KO</sup> (tumors from parous <italic>Wap-Cre<sup>+/- </sup>Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup> Trp53<sup>LoxP/LoxP</sup></italic> mice); ME<sup>KO</sup> (tumors from parous <italic>Wap-Cre<sup>+/-</sup> Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic> mice); and Control (mammary epithelium of non-parous mice of the same genotype). The NCBI SRA accession information (Project ID and Sample ID) for the exome sequence data is presented. The mean number of single nucleotide variants (SNVs) and insertions/deletions (Indels) is shown for each tumor genotype. An examination of frequent nucleotide changes revealed that ME<sup>KO</sup> tumor cells favored G to A (2/3 tumor cell lines) and JNK<sup>KO</sup> favored C to T (4/6 tumor cell lines) replacements, but no favored replacements were identified in JNK<sup>WT</sup> tumor cells. (<bold>B, C</bold>) High impact SNVs (<bold>B</bold>) and Indels (<bold>C</bold>) identified in JNK<sup>WT</sup> (n = 2), ME<sup>KO</sup> (n = 3) and JNK<sup>KO</sup> (n = 6) cells are summarized. No well-established driver mutations were found among the high impact indels or SNVs identified and there were no recurring mutations within or across genotypes.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig1-figsupp2-v1"/></fig></fig-group><p>We examined female control (ME<sup>WT</sup> and ME<sup>CRE</sup>) mice and JNK-deficient (ME<sup>KO</sup>) mice to determine whether JNK deficiency causes breast tumor development. We found no breast cancer or pre-malignant mammary lesions in a cohort of 22 control ME<sup>CRE</sup> mice (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). However, studies of a cohort of 19 control ME<sup>WT</sup> mice identified one palpable breast tumor (adenosquamous carcinoma) in a 78 wk old mouse (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In addition, mammary intraepithelial neoplasia (MIN) was detected in one ME<sup>WT</sup> mouse during microscopic analysis of tissue sections following necropsy. In contrast, the incidence of palpable breast tumors (31% of mice, median age 80 wk; p=0.037; Fisher’s Exact Test) and MIN lesions detected at necropsy (41% of mice; p=0.0084; Fisher’s Exact Test) in a cohort of 32 ME<sup>KO</sup> mice was significantly greater than ME<sup>WT</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Immunoblot analysis confirmed that the ME<sup>KO</sup> adenocarcinoma and adenosquamous carcinoma cells do not express JNK proteins (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). These data indicate that JNK deficiency promotes breast tumor development.</p><p>Microscopic analysis of tumor sections demonstrated the presence of adenosquamous carcinoma in ME<sup>WT</sup> mice, but both adenocarcinoma and adenosquamous carcinoma were detected in ME<sup>KO</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1C,E,F</xref>). The adenocarcinomas were primarily CK8 positive and variably expressed estrogen receptor (ER) and progesterone receptor (PR), while the adenosquamous carcinomas expressed CK5 and did not express ER (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). CK8 expression by ME<sup>KO</sup> adenocarcinomas is consistent with both a luminal epithelial cell origin and the expression of <italic>Wap-Cre</italic> in luminal epithelial cells (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref>). In contrast, CK5 expression by the ME<sup>KO</sup> adenosquamous carcinomas suggests that these tumor cells may partially differentiate to express a marker of myoepithelial cells.</p></sec><sec id="s2-2"><title>JNK deficiency promotes genomic instability and altered gene expression</title><p>The JNK pathway has been implicated in genome maintenance (<xref ref-type="bibr" rid="bib6">Calses et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Lu et al., 2006</xref>; <xref ref-type="bibr" rid="bib66">Van Meter et al., 2016</xref>). To test whether JNK deficiency caused defects in genome stability, we examined the exome sequences of three independent ME<sup>KO</sup> breast tumor cell lines (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). This analysis demonstrated single nucleotide variants (SNVs) and short insertions/deletions (Indels) (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), including high impact SNVs and Indels (frame-shifts and stop codons) within gene coding regions (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B,C</xref>). Moreover, many chromosome segment amplifications and deletions (copy number variations, CNVs) were detected (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). These data demonstrate that genomic instability is a consequence of JNK deficiency.</p><p>We compared gene expression profiles of three independent ME<sup>KO</sup> tumor-derived cell lines and three independent primary <italic>Wap-Cre<sup>+/-</sup></italic> epithelial cell (MEC) preparations. RNA-seq analysis identified 2217 differentially expressed genes (q &lt; 0.05, |log<sub>2</sub> Fold Change| &gt; 0.75) that formed two clusters (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Pathway over-representation analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database revealed that both clusters were highly enriched for ‘Pathways in Cancer’ (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Cluster one was also enriched for ‘Focal Adhesion’, while Cluster two was enriched for ‘Metabolic Pathways’ and ‘p53 Signaling’ (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). As expected, JNK deficiency caused reduced expression of AP1 transcription factors (<xref ref-type="bibr" rid="bib67">Ventura et al., 2003</xref>) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). We also observed reduced expression of a ‘DNA repair’ gene signature (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) in ME<sup>KO</sup> tumor cells compared with primary mammary epithelial cells (MEC), consistent with the detection of accumulated mutations in ME<sup>KO</sup> tumor cells (<xref ref-type="fig" rid="fig1">Figure 1G</xref>).</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.36389.008</object-id><label>Figure 2.</label><caption><title>JNK deficiency promotes tumor-associated gene expression.</title><p>(<bold>A–D</bold>) RNA-seq analysis was performed using primary mammary epithelial cells (MEC, n = 3) and ME<sup>KO</sup> tumor cell lines (n = 3). K-means clustering was performed on differentially expressed genes and is presented as a heatmap (<bold>A</bold>). Pathway over-representation analysis using the KEGG database was performed on genes from each of the clusters. The pathways with the 10 lowest p<sub>adj</sub> values are presented (<bold>B</bold>). The mean expression <italic>Jun</italic>, <italic>Junb</italic>, <italic>Jund</italic>, <italic>Fos</italic>, and <italic>Fosb</italic> mRNA is presented as a heatmap (<bold>C</bold>). Ingenuity Pathway Analysis of the RNA-seq data was used to predict signaling pathway activity (<bold>D</bold>). (<bold>E</bold>)<bold> </bold><italic>Wnt7b</italic> and <italic>Wnt10a</italic> expression in MEC (n = 3) and ME<sup>KO</sup> tumor cells (n = 3) is presented as the mean fragments per kilobase of exon model per million mapped fragments (FPKM) ± SEM. (<bold>F</bold>) WNT target gene expression (<italic>Axin2</italic>, <italic>Ccnd1</italic>, and <italic>Myc</italic>) in MEC (n = 3) and ME<sup>KO</sup> (n = 3) cells is presented as the mean FPKM ± SEM.</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.010</object-id><label>Figure 2—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig2-v1"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.009</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Gene set enrichment analysis demonstrates that JNK deficiency causes decreased expression of a ‘DNA Repair’ gene signature.</title><p>GSEA plot of a ‘DNA Repair’ gene signature by ME<sup>KO</sup> tumor cells compared with primary mammary epithelial cells (MEC) (p&lt;0.01).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig2-figsupp1-v1"/></fig></fig-group><p>Ingenuity Pathway Analysis (IPA) identified a significant increase in ‘WNT/β-Catenin Pathway’ activity in ME<sup>KO</sup> tumor cells compared with MEC (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Moreover, an enrichment of WNT signaling genes was found in the pathway over-representation analysis (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, Cluster 2), including increased expression of <italic>Wnt7b</italic> and <italic>Wnt10a</italic> (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) and increased expression of the WNT target genes <italic>Axin2</italic>, <italic>Ccnd1</italic>, and <italic>Myc</italic> in ME<sup>KO</sup> cells compared with MEC (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). These data suggest that ME<sup>KO</sup> tumors may exploit the WNT pathway during tumor development.</p></sec><sec id="s2-3"><title>JNK deficiency rapidly accelerates tumor development in a mouse model of breast cancer</title><p>The observation that JNK deficiency promotes breast tumorigenesis (<xref ref-type="fig" rid="fig1">Figure 1</xref>) suggests that defects in JNK signaling may accelerate tumor development in a sensitized genetic background. To test this hypothesis, we examined the genetic interaction between JNK inactivation and loss of TRP53. Since <italic>TP53</italic> is the most frequently mutated gene in human breast cancer, this model is relevant to human disease (<xref ref-type="bibr" rid="bib44">Nik-Zainal et al., 2016</xref>).</p><p>We established TRP53-deficient mice (JNK<sup>WT</sup>: <italic>Wap-Cre<sup>+/- </sup>Trp53</italic><sup>LoxP/LoxP</sup>) and TRP53/JNK compound mutant mice (JNK<sup>KO</sup>: <italic>Wap-Cre<sup>+/- </sup>Trp53<sup>LoxP/LoxP</sup> Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic>). Loss of JNK on the TRP53-deficient background dramatically accelerated tumor formation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Histological examination of the JNK<sup>WT</sup> and JNK<sup>KO</sup> tumors confirmed that the majority of lesions were adenocarcinomas (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). JNK<sup>WT</sup> and JNK<sup>KO</sup> tumors presented with variable ER and PR staining patterns (<xref ref-type="fig" rid="fig3">Figure 3C</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Moreover, both JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells primarily expressed the luminal marker CK8, consistent with a luminal epithelial cell origin, although some dispersed cells did express the myoepithelial cell marker CK5 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.36389.011</object-id><label>Figure 3.</label><caption><title>JNK deficiency accelerates tumor formation in a mouse model of breast cancer.</title><p>(<bold>A</bold>) Mammary tumor-free survival was monitored in cohorts of 26 <italic>Wap-Cre<sup>+/- </sup>Trp53</italic><sup><italic>LoxP/LoxP</italic></sup> (JNK<sup>WT</sup>) mice and 32 <italic>Wap-Cre<sup>+/- </sup>Trp53<sup>LoxP/LoxP</sup> Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic> (JNK<sup>KO</sup>) mice. Animals euthanized before a palpable mammary tumor had formed were censored in the log-rank analysis. (<bold>B</bold>) Tissue sections were prepared from JNK<sup>WT</sup> mammary tumors (n = 11) and JNK<sup>KO</sup> mammary tumors (n = 35). Representative images of H and E-stained sections from JNK<sup>WT</sup> (<italic>upper panel</italic>) and JNK<sup>KO</sup> (<italic>lower panel</italic>) mice are presented. Scale bar = 100 µm. (<bold>C</bold>) Adenocarcinoma tissue sections from JNK<sup>WT</sup> mice (<italic>upper panel</italic>) and JNK<sup>KO</sup> mice (<italic>lower panel</italic>) were stained with antibodies to (from left to right) estrogen receptor (ER), progesterone receptor (PR), cytokeratins 5 (red) and 8 (green) (CK5 and CK8 respectively), PCNA (Scale bars = 50 µm), and cleaved caspase 3 (Scale bar = 100 µm). Immunofluorescent stains were counterstained with DAPI, and peroxidase-based staining was counterstained with hematoxylin. Representative images are presented. (<bold>D, E</bold>) Exome sequencing was performed on JNK<sup>WT</sup> (n = 2) and JNK<sup>KO</sup> (n = 6) tumor cell lines. Mammary tissue from a virgin female of the same genotype (<italic>Wap-Cre<sup>+/- </sup>Trp53</italic><sup><italic>LoxP/LoxP</italic></sup> for JNK<sup>WT</sup> and <italic>Wap-Cre<sup>+/- </sup>Trp53<sup>LoxP/LoxP</sup> Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic> for JNK<sup>KO</sup>) was used as the reference genome. Representative Circos plots showing CNVs are presented for JNK<sup>WT</sup> (<bold>D</bold>) and JNK<sup>KO</sup> (<bold>E</bold>) tumor cells. The outermost ring shows chromosome ideograms. The next track indicates high (red) and moderate (yellow) impact single nucleotide variants and indels marked by rectangles and triangles, respectively. The innermost track shows chromosome amplifications and deletions, with red and blue lines indicating chromosomal fragments present at log<sub>2</sub>(ratio tumor/normal)&gt;0.2 or log<sub>2</sub>(ratio tumor/normal)&lt;−0.2, respectively.</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.015</object-id><label>Figure 3—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig3">Figure 3A</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig3-v1"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.012</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Tumors in JNK<sup>KO</sup> mice are primarily adenocarcinomas and display a spectrum of hormone receptor expression patterns.</title><p>(<bold>A</bold>) The JNK<sup>WT</sup> and JNK<sup>KO</sup> mouse cohorts are summarized. (<bold>B</bold>) Adenocarcinomas from JNK<sup>WT</sup> and JNK<sup>KO</sup> mice were stained for PR and ER and scored for expression. Numbers in parentheses indicate percentages.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig3-figsupp1-v1"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.013</object-id><label>Figure 3—figure supplement 2.</label><caption><title>Exome sequencing of Control and JNK-deficient tumor cells.</title><p>(<bold>A</bold>) Circos plots showing copy number variations (CNVs) in additional JNK<sup>KO</sup> tumor cell lines are presented. Mammary tissue from a virgin female of the same genotype (<italic>Wap-Cre<sup>+/- </sup>Trp53<sup>LoxP/LoxP </sup>Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic>) was used as the reference genome. The outermost ring shows chromosome ideograms. The next track indicates high (red) and moderate (yellow) impact single nucleotide variants and indels marked by rectangles and triangles, respectively. The innermost track shows chromosome amplifications and deletions, with red and blue lines indicating chromosomal fragments present at log<sub>2</sub>(ratio tumor/normal)&gt;0.2 or log<sub>2</sub>(ratio tumor/normal)&lt;−0.2, respectively. (<bold>B</bold>) <italic>Kras</italic> expression in MEC (n = 3), JNK<sup>WT</sup> (n = 2), and JNK<sup>KO</sup> (n = 2) cells was measured by RNA sequencing and is presented as mean FPKM ± SEM.</p><p><supplementary-material id="fig3s2sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.016</object-id><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig3-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig3-figsupp2-v1"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.014</object-id><label>Figure 3—figure supplement 3.</label><caption><title>Gene set enrichment analysis demonstrates increased expression of a ‘KRAS Signaling’ gene signature in breast tumor cells.</title><p>GSEA plots of a ‘KRAS Signaling’ gene signature by JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells compared with primary mammary epithelial cells (MEC) (p&lt;0.01).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig3-figsupp3-v1"/></fig></fig-group><p>To test whether JNK deficiency promotes tumorigenesis by disrupting the balance of proliferation and cell death, we stained tumor tissue sections with antibodies to detect the proliferation marker PCNA and the apoptotic marker cleaved caspase 3. No differences were detected in PCNA-stained sections, indicating that JNK<sup>KO</sup> tumors were not more proliferative than JNK<sup>WT</sup> tumors (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Similarly, we did not detect differences in cleaved caspase 3 staining between JNK<sup>WT</sup> and JNK<sup>KO</sup> tumors (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Collectively, these data show that JNK deficiency causes significantly accelerated disease progression without greatly changing the tumor phenotype.</p><p>To assess whether there are differences in mutational load, and to determine if there are recurring mutations or chromosomal alterations associated with the different tumor genotypes, we performed exome sequencing of JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cell lines (<xref ref-type="fig" rid="fig3">Figure 3D,E</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). High impact SNVs and Indels were identified (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B,C</xref>). CNV analysis demonstrated that chromosome six was amplified and no chromosome was consistently deleted in JNK<sup>WT</sup> tumor cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Chromosome six was also amplified in some (two of six) JNK<sup>KO</sup> tumor cells (<xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). The proto-oncogene <italic>Kras</italic> resides on chromosome six and CNV analysis demonstrated that the <italic>Kras</italic> locus was recurrently amplified in JNK<sup>WT</sup> tumor cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>) and was more highly expressed (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). The reduced amplification of the <italic>Kras</italic> locus in JNK<sup>KO</sup> tumor cells compared with JNK<sup>WT</sup> tumor cells suggests that an alternative mechanism of <italic>Kras</italic> regulation may contribute to the phenotype of these tumor cells. Indeed, increased expression of a ‘KRAS signaling’ gene signature was detected in both JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>).</p></sec><sec id="s2-4"><title>Effects of JNK deficiency on tumor-associated gene expression</title><p>We performed RNA-seq on primary mammary epithelial cells (MEC) and tumor cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) to test whether JNK deficiency caused changes in tumor-associated gene expression. An examination of genes differentially expressed (|log<sub>2</sub> Fold Change| &gt; 0.75; q &lt; 0.05) in tumor cells compared to MEC revealed distinct gene expression patterns between JNK<sup>WT</sup>, JNK<sup>KO</sup>, and ME<sup>KO</sup> tumor cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Pathway over-representation analysis using the KEGG database (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) demonstrated that up-regulated genes in JNK-deficient tumors were enriched for ‘Metabolic Pathways’ (Clusters 1 and 2), while genes up-regulated in JNK<sup>WT</sup> tumors were enriched for ‘Cytokine-Cytokine Receptor Interactions’ (Cluster 3). In contrast, down-regulated genes in all of the tumor cells were enriched for ‘Focal Adhesion Proteins’ (Cluster 4). These data indicate that JNK deficiency selectively alters a subset of tumor-associated gene expression.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.36389.017</object-id><label>Figure 4.</label><caption><title>RNA-seq analysis demonstrates that a sub-set of tumor-associated gene expression requires JNK.</title><p>(<bold>A, B</bold>) RNA isolated from primary mammary epithelial cells (MEC, n = 3) and also JNK<sup>WT</sup> (n = 2), ME<sup>KO</sup> (n = 3), and JNK<sup>KO</sup> (n = 2) tumor cell lines was sequenced. The heatmap presents k-means clustering (k = 4) of genes differentially expressed in any of the pairwise comparisons (q &lt; 0.05, |log<sub>2</sub> Fold Change| &gt; 0.75; mean) (<bold>A</bold>). Pathway over-representation analysis was performed on each of the four clusters using the KEGG database (<bold>B</bold>). The pathways with the lowest <italic>p<sub>adj</sub></italic> values for each cluster are presented. (<bold>C</bold>) Comparative analysis was performed on genes differentially expressed between MEC and the tumor cell lines using Ingenuity Pathway Analysis (IPA). Heatmaps show the predicted activation (Activation z-score) of canonical pathways involved in immune (<italic>left panel</italic>) and integrin/cytoskeleton (<italic>right panel</italic>) signaling (cutoff score = 1.31; equates to p=0.049 using Fisher’s Exact Test).</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.020</object-id><label>Figure 4—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig4-v1"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.018</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Gene expression analysis of control and JNK-deficient tumor cells.</title><p>(<bold>A</bold>) Summary of the RNA sequencing data together with database accession information (GEO accession numbers and Sample ID). The number of samples per biological group is shown in parentheses. (<bold>B</bold>) Venn diagram showing differentially expressed (DE) genes in JNK<sup>WT</sup> (n = 2), ME<sup>KO</sup> (n = 3), and JNK<sup>KO</sup> (n = 2) tumors compared to MEC (n = 3). (<bold>C</bold>) Ingenuity Pathway Analysis was used to predict pathway activation and inhibition in JNK<sup>WT</sup> (n = 2), ME<sup>KO</sup> (n = 3), and JNK<sup>KO</sup> (n = 2) tumor cells. The heatmap shows pathways ranked (top to bottom) by their score (total -log<sub>10</sub><italic>p</italic> of Fisher’s Exact Test across the tumors). The top 100 pathways with lowest -log<sub>10</sub><italic>p</italic> are shown. Coloring corresponds to the activation z-Score, with green representing inhibited pathways and red activated pathways. A cutoff of score = 1.31 was set (equates to p=0.049; Fisher’s Exact Test).</p><p><supplementary-material id="fig4s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.021</object-id><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig4-figsupp1-v1"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.019</object-id><label>Figure 4—figure supplement 2.</label><caption><title>Comparison of signaling pathway activity in control and JNK-deficient tumor cells.</title><p>(<bold>A</bold>) Two independently-derived JNK<sup>WT</sup> tumor cell lines (JNK<sup>WT</sup> 1 and JNK<sup>WT</sup> 2) were left untreated (-) or were exposed (+) to 60 J/m<sup>2</sup> ultraviolet light. Lysates from these cells were harvested at 30 min post-irradiation and were examined by immunoblot analysis by probing with antibodies to α-Tubulin, p-JNK, JNK, p-cJUN, and cJUN. (<bold>B</bold>) JNK<sup>WT</sup> (n = 2) and JNK<sup>KO</sup> (n = 6) tumor cell lines were cultured and protein lysates were prepared for immunoblot analysis. Lysates were probed for JNK, p-ERK, ERK2, p-p38, p38, p-AKT (T308), p-AKT (S473), AKT, and α-Tubulin. Representative blots showing one JNK<sup>WT</sup> cell line and three JNK<sup>KO</sup> cell lines are presented.</p><p><supplementary-material id="fig4s2sdata2"><object-id pub-id-type="doi">10.7554/eLife.36389.022</object-id><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Source image data for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>.</title><p>Whole immunoblot scans are presented and the region used to construct <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref> is outlined.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-36389-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata3"><object-id pub-id-type="doi">10.7554/eLife.36389.023</object-id><label>Figure 4—figure supplement 2—source data 2.</label><caption><title>Source image data for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>.</title><p>Whole immunoblot scans are presented and the region used to construct <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref> is outlined.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-36389-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig4-figsupp2-v1"/></fig></fig-group><p>To understand how JNK deficiency may alter tumor-signaling pathways, we used IPA to predict pathway activation status by examining differential expression between each tumor type and MEC. The pathways were ranked by Activation z-Score (total -log<sub>10</sub><italic>p</italic> of Fisher’s Exact Test across the tumors) and the top 100 were considered (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Two dominant categories emerged from the comparative analysis: down-regulated ‘Chemokine/Cytokine Signaling’; and down-regulated ‘Integrin/Cytoskeleton Signaling’ (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><p>We also examined signaling pathways by immunoblot analysis. Studies of JNK<sup>WT</sup> tumor cells demonstrated the presence of a functional JNK signaling pathway, including stress-induced phosphorylation of both JNK and cJUN (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). However, JNK was not detected in JNK<sup>KO</sup> tumor cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). The activation state of other MAPK pathways (ERK and p38) and the AKT pathway were similar between JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>).</p></sec><sec id="s2-5"><title>JNK deficiency does not increase tumor stem cell activity</title><p>The increased mammary tumor formation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) caused by JNK deficiency may reflect a role of JNK in tumor stem cells. To examine this potential role of JNK, we monitored mammosphere formation and maintenance using JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells. No evidence of increased mammosphere propagation by the JNK<sup>KO</sup> tumor cells was obtained (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>). Moreover, we did not detect enhanced sphere formation by ME<sup>KO</sup> tumor cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A,B</xref>). Staining of agarose-embedded JNK<sup>WT</sup> and JNK<sup>KO</sup> mammospheres revealed a similar organization with peripheral CK5<sup>+</sup> cells and central CK8<sup>+</sup> cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Finally, the expression of stem cell markers (<italic>Bmi1</italic>, <italic>Nanog</italic>, and <italic>Pou5f1</italic>) was not significantly different between JNK<sup>WT</sup> and JNK<sup>KO</sup> mammospheres (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). This analysis does not support the conclusion that differences in cancer stem cell activity account for the accelerated tumor formation by JNK<sup>KO</sup> mice compared with JNK<sup>WT</sup> mice.</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.36389.024</object-id><label>Figure 5.</label><caption><title>Stem cell populations are comparable in JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells.</title><p>(<bold>A</bold>) JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells formed mammospheres when grown in suspension. Two independent cell lines were tested for each genotype. Representative phase contrast (<italic>upper panel</italic>) and H and E-stained agarose-embedded sphere sections (<italic>lower panel</italic>) are presented. Representative images are presented. Scale bar = 100 µm. (<bold>B</bold>) The number of mammospheres formed per 1000 plated cells each passage (P) was quantitated for JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells. Two independent cell lines were tested for each genotype. The data presented are the mean ± SEM (n = 3 independent experiments). No significant differences were observed (p&gt;0.05). (<bold>C</bold>) Representative agarose-embedded mammosphere sections stained with antibodies to cytokeratin 5 (CK5, red) and cytokeratin 8 (CK8, green), and counterstained with DAPI are presented. Scale bar = 50 µm. (<bold>D</bold>) RNA was isolated from JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cell mammospheres at different passages to quantify mRNA expression of <italic>Bmi1</italic>, <italic>Nanog</italic>, and <italic>Pou5f1</italic>. Two independent cell lines were tested for each genotype. The data presented are the mean ± SEM (n = 2 independent experiments). No significant differences were observed (p&gt;0.05).</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.026</object-id><label>Figure 5—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig5-v1"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36389.025</object-id><label>Figure 5—figure supplement 1.</label><caption><title>JNK-deficient tumor cells do not exhibit enhanced tumor stem cell activity.</title><p>(<bold>A</bold>) JNK<sup>WT</sup> (n = 2) and ME<sup>KO</sup> (n = 3) tumor cells grown in suspension formed mammospheres. Representative phase contrast (<italic>upper panel</italic>) and agarose-embedded H and E-stained sections (<italic>lower panel</italic>) are shown. Scale bar = 100 µm. (<bold>B</bold>) Sphere formation per 1000 tumor cells plated over two passages (P) was quantitated for two JNK<sup>WT</sup> cell lines and three ME<sup>KO</sup> cell lines (mean ± SEM; n = 3 independent experiments).</p><p><supplementary-material id="fig5s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.027</object-id><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig5-figsupp1-v1"/></fig></fig-group></sec><sec id="s2-6"><title>JNK deficiency does not increase tumor cell proliferation, but does promote survival</title><p>Transformed cells co-opt cellular processes to block anti-proliferative and death mechanisms while increasing cell proliferation, invasion, and migration (<xref ref-type="bibr" rid="bib27">Hanahan and Weinberg, 2011</xref>). A change in one of these processes may account for the increased tumor formation detected in JNK<sup>KO</sup> mice. No differences between JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cell proliferation were detected (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Similarly, we found no difference in JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cell migration during wound healing (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) or in response to a serum gradient (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Moreover, JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cell invasion through matrigel-coated membranes (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and collagen I-filled wounds (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) was similar. These data demonstrate that JNK deficiency does not alter breast tumor cell proliferation, invasion, or migration. Consistent with this conclusion, we found no differences between the growth of JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells in orthotopically transplanted syngeneic mice (<xref ref-type="fig" rid="fig6">Figure 6E–G</xref>).</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.36389.028</object-id><label>Figure 6.</label><caption><title>JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells exhibit similar phenotypes.</title><p>(<bold>A</bold>) JNK<sup>WT</sup> (n = 2) and JNK<sup>KO</sup> (n = 6) tumor cell lines were cultured (8 hr) in growth media and the change in confluence was measured using an IncuCyte ZOOM (mean ± SEM). No significant differences (p&gt;0.05) were observed. Similar data were obtained in four independent experiments. (<bold>B</bold>) Monolayers of JNK<sup>WT</sup> (n = 2) and JNK<sup>KO</sup> (n = 4) cells were wounded and cell migration rates were assessed by measuring the change in wound width 48 hr after wounding using an IncuCyte ZOOM (mean ± SEM). No significant differences (p&gt;0.05) were observed. Similar data were obtained in two independent experiments. (<bold>C</bold>) JNK<sup>WT</sup> (n = 2) and JNK<sup>KO</sup> (n = 6) tumor cell chemotaxis in response to a serum gradient in the absence (Control) or presence of Matrigel was examined (mean ± SEM). No significant differences were observed (p&gt;0.05). Similar data were obtained in two independent experiments. (<bold>D</bold>) Monolayers of JNK<sup>WT</sup> (n = 2) and JNK<sup>KO</sup> (n = 3) tumor cells were wounded, overlayed with 0.5 mg/ml collagen I in growth serum, and cultured for up to 48 hr in media containing 2% serum. Tumor cell migration into the collagen-filled wound was quantitated by measuring cell density in the initial wound area using an IncuCyte ZOOM (mean ± SEM). No significant differences were observed (p&gt;0.05). Similar data were obtained in two independent experiments. (<bold>E–G</bold>) Orthotopic transplantation of JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells (two independent cell lines per genotype) into the mammary fat pads of 26 (JNK<sup>WT</sup>) and 27 (JNK<sup>KO</sup>) syngeneic wild-type host mice was performed using 2 × 10<sup>6</sup> tumor cells (<bold>E</bold>). Orthotopic transplantation of 0.5 × 10<sup>6</sup> tumor cells was performed using 30 (JNK<sup>WT</sup>) and 26 (JNK<sup>KO</sup>) syngeneic wild-type host mice (<bold>F</bold>). No significant differences were observed (p&gt;0.05). Representative H and E-stained tumor sections from JNK<sup>WT</sup> (<italic>upper panel</italic>) and JNK<sup>KO</sup> (<italic>lower panel</italic>) tumors are presented (<bold>G</bold>). Scale bar = 100 µm. (<bold>H, I</bold>) JNK<sup>WT</sup> (n = 2) and JNK<sup>KO</sup> (n = 4) tumor cell lines were cultured in soft agar and colony formation was quantitated (mean ± SEM) (<bold>H</bold>). Similar data were obtained from two independent experiments and representative images of crystal violet-stained colonies are presented (<bold>I</bold>). Scale bar = 100 µm. (<bold>J</bold>) Two JNK<sup>WT</sup> and five JNK<sup>KO</sup> tumor cell lines were cultured in suspension (24 hr) and apoptotic cells (7AAD<sup>-</sup> annexin V<sup>+</sup>) were quantitated by flow cytometry (mean ± SEM; n = 7 for JNK<sup>WT</sup> and n = 16 for JNK<sup>KO</sup>).</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.029</object-id><label>Figure 6—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig6-v1"/></fig><p>While many properties of JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells are similar (<xref ref-type="fig" rid="fig6">Figure 6A–G</xref>), we did detect some JNK-dependent differences in the tumor cell phenotype (<xref ref-type="fig" rid="fig6">Figure 6H–J</xref>). Thus, JNK<sup>KO</sup> tumor cells formed more colonies than JNK<sup>WT</sup> tumor cells when grown in soft agar (<xref ref-type="fig" rid="fig6">Figure 6H,I</xref>) and JNK<sup>KO</sup> cells exhibited greater resistance to anoikis than JNK<sup>WT</sup> tumor cells (<xref ref-type="fig" rid="fig6">Figure 6J</xref>). These data indicate that JNK deficiency can promote tumor cell survival.</p></sec><sec id="s2-7"><title>JNK deficiency causes early disease initiation</title><p>Comparative studies of JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells demonstrated that JNK-deficiency does not contribute to differences in proliferation, migration, or invasion phenotypes in vitro (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref>) or to tumor growth in orthotopically transplanted syngeneic mice (<xref ref-type="fig" rid="fig6">Figure 6E–G</xref>). We therefore considered the possibility that JNK may influence tumor initiation rather than the function of fully developed tumor cells. To test this hypothesis, we examined sections of mammary glands from female mice at 18 weeks after gene ablation. JNK<sup>WT</sup> mice presented normal mammary gland morphology (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). In contrast, multifocal mammary intraepithelial neoplasia (MIN) was observed in JNK<sup>KO</sup> glands (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). The presence of MIN lesions in young JNK<sup>KO</sup> mice indicates that JNK-deficient mammary epithelial cells exhibit defects in apical-basal polarity, a hallmark of mammary tumor development (<xref ref-type="bibr" rid="bib25">Halaoui et al., 2017</xref>; <xref ref-type="bibr" rid="bib81">Zhan et al., 2008</xref>). Moreover, it is likely that mammary tumor development is further promoted by the increased survival of JNK<sup>KO</sup> cells in vitro (<xref ref-type="fig" rid="fig6">Figure 6H–J</xref>) and increased proliferation of JNK<sup>KO</sup> epithelial cells compared with JNK<sup>WT</sup> epithelial cells in vivo (<xref ref-type="fig" rid="fig7">Figure 7B,C</xref>). These data indicate that one physiological function of JNK in mammary epithelial cells is to suppress breast cancer development by preventing the initiation of carcinogenesis.</p><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.36389.030</object-id><label>Figure 7.</label><caption><title>JNK deficiency promotes early disease lesions.</title><p>(<bold>A</bold>) Eighteen weeks after gene deletion, tissue sections were prepared from mammary glands of JNK<sup>WT</sup> (n = 5) and JNK<sup>KO</sup> (n = 12) female mice. The mice were not matched for estrus cycle. Representative H and E-stained sections are presented. Scale bar = 100 µm. (<bold>B, C</bold>) Proliferation was examined in mammary glands at 18 weeks after gene ablation by staining tissue sections with an antibody to PCNA (JNK<sup>WT </sup>n = 4 mice, JNK<sup>KO </sup>n = 5 mice). Representative PCNA-stained and DAPI counter-stained glands are presented (B, Scale bar = 50 µm). The percent of PCNA<sup>+</sup> cells was quantified (mean ± SEM) (<bold>C</bold>).</p><p><supplementary-material id="fig7sdata1"><object-id pub-id-type="doi">10.7554/eLife.36389.031</object-id><label>Figure 7—source data 1.</label><caption><title>Spreadsheet of source data for <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36389-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-36389-fig7-v1"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The frequent mutation of the JNK pathway in human breast cancer (including the genes <italic>MAP3K1</italic>, <italic>MAP2K4</italic>, and <italic>MAP2K7</italic>) implicates reduced JNK signaling in the etiology of mammary carcinoma (<xref ref-type="bibr" rid="bib3">Banerji et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib14">Ciriello et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Ellis et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Kan et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Nik-Zainal et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Shah et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Stephens et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Wang et al., 2014</xref>). Mutation of <italic>Mapk8</italic> (encodes JNK1) and <italic>Mapk9</italic> (encodes JNK2) is not frequently detected, most likely because of the functional redundancy of these JNK isoforms (<xref ref-type="bibr" rid="bib16">Davis, 2000</xref>). In contrast, MAP2K4 and MAP2K7 serve as non-redundant activators of JNK and mutation of either <italic>MAP2K4</italic> or <italic>MAP2K7</italic> causes JNK inhibition (<xref ref-type="bibr" rid="bib62">Tournier et al., 2001</xref>). Similarly, MAP3K1 can act in a non-redundant manner to activate JNK (<xref ref-type="bibr" rid="bib80">Yujiri et al., 2000</xref>). Tumor-associated ablation or mutation of these genes therefore causes JNK inhibition. Moreover, JNK signaling is also inhibited by phosphorylation of MAP2K4 by AKT (<xref ref-type="bibr" rid="bib45">Park et al., 2002</xref>) in breast tumors with AKT activation caused by ‘driver’ mutations in <italic>PTEN</italic> or <italic>PIK3CA</italic> (<xref ref-type="bibr" rid="bib19">Garraway and Lander, 2013</xref>). Suppression of JNK signaling is therefore a characteristic of many breast cancers. Nevertheless, the significance of JNK pathway inactivation in breast cancer is unclear (<xref ref-type="bibr" rid="bib10">Cellurale et al., 2012</xref>; <xref ref-type="bibr" rid="bib11">Cellurale et al., 2010</xref>). Here, we demonstrate that loss of JNK signaling promotes murine breast cancer development (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Furthermore, JNK deficiency accelerated tumor development in a murine model of breast cancer (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The frequent JNK pathway <italic>loss-of-function</italic> mutations in human breast cancer may therefore represent ‘driver’ mutations that promote tumor development.</p><p>We find that JNK loss plays a key role at the early stages of breast cancer development by promoting mammary gland neoplasia (<xref ref-type="fig" rid="fig7">Figure 7</xref>). This observation likely accounts for the effect of mutational inactivation of JNK signaling to promote tumor development (<xref ref-type="fig" rid="fig1">Figure 1 and 3</xref>). In contrast to this tumor-suppressive role of JNK during early stages of carcinogenesis (<xref ref-type="fig" rid="fig7">Figure 7</xref>), JNK does not markedly influence the late-stage tumor phenotype (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Thus, JNK does not change tumor cell proliferation, invasion or migration in vitro or tumor formation in orthotopically transplanted mice in vivo (<xref ref-type="fig" rid="fig6">Figure 6</xref>). However, JNK deficiency does repress tumor cell anoikis and promotes growth in soft agar in vitro (<xref ref-type="fig" rid="fig6">Figure 6</xref>). JNK therefore plays a major role in early tumor development, but only a minor role in established tumors.</p><p>An important question relates to the mechanism of breast tumor suppression by the JNK signaling pathway. Part of the mechanism may reflect the pro-apoptotic role of JNK (<xref ref-type="bibr" rid="bib63">Tournier et al., 2000</xref>). Mutations in key genes can enable epithelial cell survival in the luminal space, resulting in ductal carcinoma in situ (DCIS) and cancer (<xref ref-type="bibr" rid="bib25">Halaoui et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Leung and Brugge, 2012</xref>; <xref ref-type="bibr" rid="bib48">Pradeep et al., 2012</xref>; <xref ref-type="bibr" rid="bib60">Taraseviciute et al., 2010</xref>). Indeed, JNK deficiency has been shown to impair efficient epithelial cell death in response to cell detachment (anoikis) in vitro and cause both occlusion of mammary ducts (<xref ref-type="bibr" rid="bib10">Cellurale et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Girnius and Davis, 2017</xref>) and delayed involution (<xref ref-type="bibr" rid="bib22">Girnius et al., 2018</xref>) in vivo. It is therefore possible that these types of cell survival responses in the mammary epithelium may contribute to tumor development. However, this mechanism may not be sufficient to account for the tumor formation caused by JNK deficiency (<xref ref-type="fig" rid="fig1">Figure 1</xref>) or the observed acceleration of tumor formation caused by JNK deficiency in a mouse model of breast cancer (<xref ref-type="fig" rid="fig3">Figure 3</xref>). For example, both JNK and p38 MAPK promote mammary gland epithelial cell anoikis by a BIM-dependent mechanism and are required for luminal clearance of mammary ducts (<xref ref-type="bibr" rid="bib10">Cellurale et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Girnius and Davis, 2017</xref>; <xref ref-type="bibr" rid="bib72">Wen et al., 2011</xref>), but JNK inhibition promotes breast cancer (<xref ref-type="fig" rid="fig1">Figure 1 and 3</xref>) while p38 MAPK pathway inhibition suppresses breast cancer development and promotes the early dissemination of tumor cells (<xref ref-type="bibr" rid="bib17">Del Barco Barrantes et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">Gawrzak et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Harper et al., 2016</xref>). These data indicate that anoikis defects and ductal occlusion by detached epithelial cells caused by stress-activated MAPK inhibition is not sufficient for tumor formation. This reasoning implicates a second pathway of JNK-mediated suppression of mammary tumor development.</p><p>Insight into JNK-mediated tumor suppression was obtained from the analysis of tumor genomic DNA. We found that JNK deficiency caused genomic instability associated with widespread SNVs, Indels, and CNVs (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). It is likely that these genetic changes caused by JNK deficiency contribute to tumor development. This genetic instability reflects the function of JNK to promote genome maintenance in response to stress. Examples include JNK-mediated phosphorylation of SIRT6 to stimulate double-stranded DNA break repair (<xref ref-type="bibr" rid="bib66">Van Meter et al., 2016</xref>) and JNK-mediated phosphorylation of DGCR8 to induce transcription-coupled nucleotide excision repair (<xref ref-type="bibr" rid="bib6">Calses et al., 2017</xref>). Loss of JNK signaling would therefore be expected to cause defects in DNA repair that result in increased genomic instability. Indeed, our analysis demonstrates that JNK deficiency in the mammary epithelium causes genomic instability (<xref ref-type="fig" rid="fig1">Figure 1G</xref>) and breast cancer (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). JNK deficiency may therefore increase the sensitivity of tumor cells to drugs that cause DNA damage. This represents a potential opportunity for the design of therapeutic strategies for the treatment of tumors with defects in JNK signaling.</p><p>The TRP53 pathway is known to be important for genome stability and tumor suppression. Our data demonstrate that the JNK pathway similarly promotes genome stability and tumor suppression. The number of SNVs and indels caused by TRP53 deficiency was greater than that caused by JNK deficiency. Nevertheless, the number of CNVs were similar on both genetic backgrounds. These observations indicate that while both TRP53-deficiency and JNK-deficiency can cause genomic instability, the mechanisms engaged by these two pathways may be different.</p><p>The identification of JNK pathway mutations as ‘driver’ mutations for breast cancer was not anticipated. For example, the JNK pathway can promote cell proliferation and survival through regulation of AP1 transcription factors (<xref ref-type="bibr" rid="bib15">Das et al., 2007</xref>; <xref ref-type="bibr" rid="bib33">Lamb et al., 2003</xref>; <xref ref-type="bibr" rid="bib67">Ventura et al., 2003</xref>). Indeed, the JNK/JUN signaling pathway may promote the proliferation of some breast tumor cells in vitro (<xref ref-type="bibr" rid="bib24">Guo et al., 2006</xref>; <xref ref-type="bibr" rid="bib76">Xie et al., 2017</xref>). It is therefore possible that JNK signaling may have pro-oncogenic functions in certain tumor types or under specific conditions (<xref ref-type="bibr" rid="bib74">Whitmarsh and Davis, 2007</xref>). Nevertheless, our analysis establishes that a major role of JNK signaling in the breast epithelium is tumor suppression (<xref ref-type="fig" rid="fig1">Figure 1 and 3</xref>). This role of JNK signaling is consistent with the discovery of frequent JNK pathway gene ablation and mutation in human breast cancer (<xref ref-type="bibr" rid="bib3">Banerji et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib14">Ciriello et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Ellis et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Kan et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Nik-Zainal et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Shah et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Stephens et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Wang et al., 2014</xref>).</p><p>The major conclusions of this study are that: (1) JNK deficiency in the mammary epithelium can cause murine breast cancer; and (2) JNK deficiency rapidly accelerates tumor development in a mouse model of breast cancer. These observations indicate that JNK can act as a breast cancer tumor suppressor. This is a significant finding because frequent mutational inactivation of genes that encode JNK pathway components (e.g. <italic>MAP2K4</italic> and <italic>MAP3K1</italic>) are detected in human breast cancer (<xref ref-type="bibr" rid="bib19">Garraway and Lander, 2013</xref>). However, it should be noted that the compound disruption of JNK expression that we have studied most likely differs from the loss of individual JNK pathway components (e.g. MAP2K4 and MAP3K1) because of partial compensation by alternative signaling molecules, including MAP2K7 and members of the MAP3K family. Whether reduced JNK activity caused by loss of MAP2K4 or MAP3K1 phenocopies the effects of compound JNK deficiency on breast cancer is unclear. An important goal for future studies will be to directly test the effect of <italic>MAP2K4</italic> and <italic>MAP3K1</italic> gene mutation on breast cancer.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p>We have previously described <italic>Mapk8<sup>LoxP/LoxP</sup> Mapk9<sup>LoxP/LoxP</sup></italic> mice (<xref ref-type="bibr" rid="bib26">Han et al., 2013</xref>). C57BL6/J (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:000664">IMSR_JAX:000664</ext-link>), B6129-TG(Wap-cre)11738Mam/J (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:008735">IMSR_JAX:008735</ext-link>) (<xref ref-type="bibr" rid="bib69">Wagner et al., 1997</xref>), B6.129P2-<italic>Trp53<sup>tm1Brn</sup></italic>/J (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:008462">IMSR_JAX:008462</ext-link>) (<xref ref-type="bibr" rid="bib41">Marino et al., 2000</xref>), and B6.129(Cg)-Gt(ROSA)26Sor<sup>tm4(ACTB-tdTomato,-EGFP)Luo</sup>/J mice (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:007676">IMSR_JAX:007676</ext-link>) (<xref ref-type="bibr" rid="bib42">Muzumdar et al., 2007</xref>) were purchased from The Jackson Laboratories (Bar Harbor, ME). All mice were on a C57BL6/J strain background (10 generations back-crossed). Female mice were bred at 10–12 weeks of age and monitored for tumor development by palpation following weaning. Reasons for euthanasia included a tumor of 1 cm in diameter, ulceration due to the tumor, poor health, or weight loss (&gt;20% body weight). The animals were housed in a specific pathogen-free facility accredited by the American Association of Laboratory Animal Care (AALAC).</p></sec><sec id="s4-2"><title>Tumor-derived cell lines</title><p>Tumors were harvested and placed in DMEM/F12 medium supplemented with 1% penicillin/streptomycin and 1% nystatin (Thermo Fisher Scientific, Waltham, MA). The tissue was washed with phosphate-buffered saline (PBS), minced, and digested (37°C for up to 2 hr, shaking) in DMEM supplemented with 2 mg/ml collagenase, 0.1% trypsin, and 1% penicillin/streptomycin. Following digestion, cells were pelleted and re-suspended in DMEM/F12 supplemented with 2% fetal bovine serum and 1% penicillin/streptomycin, then plated on collagen I (Thermo Fisher Scientific Cat# A1048301) coated dishes. After two passages, the cells were plated on standard tissue culture dishes and maintained in Growth Medium (DMEM/F12 supplemented with 10% fetal bovine serum plus 1% penicillin/streptomycin) prior to cryogenic storage.</p></sec><sec id="s4-3"><title>Genotype analysis</title><p>Genomic DNA was genotyped using a PCR-based method. <italic>Mapk8<sup>LoxP</sup></italic> (540 bp) and <italic>Mapk8<sup>+</sup></italic> (330 bp) were detected using amplimers 5’-AGGATTTATGCCCTCTGCTTGTC-3’ and 5’-GACCACTGTTCCAATTTCCATCC-3’. <italic>Mapk9<sup>LoxP</sup></italic> (264 bp) and <italic>Mapk9<sup>+</sup></italic> (224 bp) were detected using amplimers 5’-GTTTTGTAAAGGGAGCCGAC-3’ and 5’-CCTGACTACTGAGCCTGGTTTCTC-3’. <italic>Trp53<sup>LoxP</sup></italic> (370 bp) and <italic>Trp53<sup>+</sup></italic> (288 bp) were detected using amplimers 5’-AGCACATAGGAGGCAGAGAC-3’ and 5’-CACAAAAACAGGTTAAACCCAG-3’. <italic>Cre<sup>+</sup></italic> (450 bp) was detected using amplimers 5’-TTACTGACCGTACACCAAATTTGCCTGC-3’ and 5’-CCTGGCAGCGATCGCTATTTTCCATGAGTG-3’. <italic>Mapk8<sup>Δ</sup></italic> (395 bp), <italic>Mapk8<sup>+</sup></italic> (1550 bp), and <italic>Mapk8<sup>LoxP</sup></italic> (1,095 bp) were detected using amplimers 5’-CCTCAGGAAGAAAGGGCTTATTTC-3’ and 5’-GAACCACTGTTCCAATTTCCATCC-3’. <italic>Mapk9<sup>Δ</sup></italic> (400 bp) and <italic>Mapk9<sup>LoxP</sup></italic> (560 bp) were detected using 5’-GGAATGTTTGGTCCTTTAG-3’, 5’-GCTATTCAGAGTTAAGTG-3’, and 5’-TTCATTCTAAGCTCAGACTC-3’. <italic>Trp53<sup>Δ</sup></italic> (612 bp) was detected using amplimers 5’-GAAGACAGAAAAGGGGAGGG-3’ and 5’-CACAAAAACAGGTTAAACCCAG-3’.</p></sec><sec id="s4-4"><title>Orthotopic transplantation</title><p>Tumor-derived cell lines were screened for common pathogens using the Rapidmap panel 21 (Taconic Biosciences, New York, NY). The cells were pelleted and washed five times with PBS before resuspension at a final concentration of 2 × 10<sup>6</sup> or 0.5 × 10<sup>6</sup> cells/40 µl of PBS. A 26-guage needle was used to inject the cells into the thoracic mammary gland. The presence of tumors was monitored weekly and palpable tumors were measured using calipers. Mice meeting euthanasia criteria or mice that remained 80 days post-inoculation were euthanized.</p></sec><sec id="s4-5"><title>Cell proliferation</title><p>Cells were seeded in 96-well plates (1,000 cells/well) and cultured in an IncuCyte Zoom (Essen Bioscience). The cells were kept in growth media and fed every 2 days for the duration of the assay. Images were taken every 4 hr and cell confluence was measured at these time points.</p></sec><sec id="s4-6"><title>Soft agar growth</title><p>Agarose (Lonza, Basel, CH) was dissolved in water (4 or 2% (w/v) solution) and autoclaved. The 4% agarose was mixed with growth media to yield a 1% agarose solution, which was plated and allowed to solidify (4°C). Tumor cells in growth media (100,000/6 cm dish) were mixed with the 2% agarose to a final concentration of 0.5% agarose, and overlayed onto the solidified 1% agarose. The cells were fed with Growth Medium every 3 ~ 4 days for the duration of the assay. After 3 weeks, the cells were fixed with 100% methanol (−20°C) and stained with 0.1% crystal violet dissolved in 20% methanol/80% PBS. Images were taken using a Zeiss AxioVert 200M microscope. Six 10x-fields/plate were used to quantify colony formation (≥3000 pixels<sup>2</sup>) using FIJI software (<xref ref-type="bibr" rid="bib54">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-7"><title>Mammosphere assay</title><p>Tumor cells were seeded 25,000/ml in a 24-well ultra-low attachment plate in DMEM/F12 media containing 1% penicillin/streptomycin, B27 supplement (1:50), 20 ng/ml bFGF, 2.5 µg/ml insulin, and 20 ng/ml EGF. Six wells were plated for each cell line. Three to four days later, before passaging, colonies larger than 50 µm were counted using a Zeiss AxioVert 200M microscope. The spheres were dissociated by incubation (15 min) with 0.25% trypsin (Thermo Fisher Scientific) with pipetting. The digestion was terminated by addition of 0.5% soybean trypsin inhibitor (ATCC) and single cells were plated. Spheres used for embedding in agarose or for RNA isolation were treated similarly, but were cultured in 100 mm ultra-low attachment dishes. Spheres prepared for embedding were resuspended in 4% agarose (IBI Scientific Cat# IB70050) and fixed in 10% formalin before processing.</p></sec><sec id="s4-8"><title>Anoikis assay</title><p>Tumor cells were suspended in serum-free DMEM/F12 media with 0.5% methylcellulose (Millipore-Sigma), placed in poly-HEMA (Millipore-Sigma) coated plates (1.2 × 10<sup>5</sup> cells/ml), and incubated for 24 hr. After incubation, the cells were washed twice with PBS, then stained with phycoerythrin-conjugated Annexin V and 7-aminoactinomycin D (7-AAD) using the PE annexin apoptosis detection kit I (BD Pharmingen #559763). A FACSCalibur (BD Bioscience) was used to quantify the apoptotic cells (7AAD<sup>-</sup> Annexin V<sup>+</sup>). Single-stained controls were used to gate 7AAD<sup>-</sup> and 7AAD<sup>+</sup> cells while cells suspended for 1 hr were used to define the annexin V<sup>+</sup> and annexin V<sup>-</sup> populations. FlowJo version 9.7.6 (Tree Star) was used to analyze the data (<xref ref-type="bibr" rid="bib21">Girnius and Davis, 2017</xref>).</p></sec><sec id="s4-9"><title>Wound healing</title><p>Tumor cells were seeded at a density of 100,000 cells/well in a 96-well ImageLock plate (Essen Bioscience) and allowed to adhere overnight. The following day, a Wound Maker (Essen Bioscience) was used to scratch the confluent monolayers of cells. The cells were washed two times with PBS and then maintained in serum-free media for the remainder of the assay. Invasion assays were performed using cells plated in 96-well ImageLock plates coated with 300 µg/ml collagen I. Cells adhered overnight, were scratched using a WoundMaker, and washed twice with media before being placed on ice (5 min). The cells were then overlayed with growth media containing collagen I (0.5 mg/ml). The cells were incubated (30 min at 37°C) to solidify the collagen prior to the addition of DMEM/F12 supplemented with 2% FBS. All plates were imaged every 4 hr using an IncuCyte Zoom (Essen Bioscience).</p></sec><sec id="s4-10"><title>Transwell migration</title><p>Tumor cells (30,000 cells/well) were plated in triplicate using Growth Medium in transwells with 8 µm pores (Millipore Sigma) and allowed to adhere. For invasion assays, inserts coated with Matrigel (Millipore Sigma) were rehydrated according to the manufacturer’s instructions before plating cells. To create a serum gradient, media from the upper chambers was replaced with serum-free media. Cells were allowed to migrate for 16–20 hr. Remaining cells in the upper chambers were removed with a cotton swab, then the inserts were fixed with 100% methanol (20 min, −20°C), washed three times with PBS, and stained with 2-(4-amidinophenyl)−1 hr -indole-6-carboxamidine (DAPI). The insert membranes were removed with a scalpel and mounted on a slide for examination using a Zeiss Axiovert 200M microscope. Two to three images at 10x magnification were taken for each membrane. FIJI was used to quantify the migrating cells (<xref ref-type="bibr" rid="bib54">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-11"><title>Histological analysis</title><p>Mammary glands #2–5 were harvested, fixed in 10% formalin, dehydrated, and embedded in paraffin. Hematoxylin and eosin-stained sections (5 µm) were reviewed by a board-certified veterinary pathologist to identify and classify proliferative lesions (<xref ref-type="bibr" rid="bib8">Cardiff et al., 2000</xref>). To detect proliferation, sections were treated with the endogenous biotin blocking kit (Thermo Fisher Scientific E21390), prior to incubation with a biotin-conjugated antibody to PCNA (Thermo Fisher Scientific Cat# 13–3940 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2533017">AB_2533017</ext-link>; dilution 1:50), and an AlexaFluor 633-conjugated streptavidin (Thermo Fisher Scientific Cat# S-21375 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2313500">AB_2313500</ext-link>). For PCNA quantification 49–50 fields were examined across JNK<sup>WT</sup> (n = 4) and JNK<sup>KO</sup> (n = 5) mice. PCNA positive duct cells were normalized to the total number of duct cells in the field examined. Additional sections were stained with cleaved-caspase-3 (Cell Signaling Technology Cat# 9662 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331439">AB_331439</ext-link>; 1:100), cytokeratin 5 (BioLegend Cat# 905501 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2565050">AB_2565050</ext-link>; 1:50), cytokeratin 8 (DSHB Cat# TROMA-I RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_531826">AB_531826</ext-link>; 1:100), GFP (Thermo Fisher Scientific Cat# A21311 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_221477">AB_221477</ext-link>; 1:100), estrogen receptor (Santa Cruz Biotechnology Cat# sc-542 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_631470">AB_631470</ext-link>; 1:500), and progesterone receptor (Santa Cruz Biotechnology Cat# sc-538 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_632263">AB_632263</ext-link>; 1:300). For immunohistochemistry, a biotinylated rabbit antibody (Biogenex Cat# HK340-5K) in conjunction with streptavidin-conjugated horseradish peroxidase (Vector Laboratories Cat# PK-6100) and 3,3’-diaminobenzidene (Vector Laboratories Cat# SK-4100) was used to detect the primary antibody. Sections were then counterstained with hematoxylin (Fisher Scientific) and pictures were taken using a Zeiss Axiovert. AlexaFluor 546 conjugated-goat anti-rabbit IgG (H + L) antibody (Thermo Fisher Scientific Cat# A11035 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_143051">AB_143051</ext-link>) and AlexaFluor 488 conjugated-goat anti-rat IgG (H + L) antibody (Thermo Fisher Scientific Cat# A11006 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_141373">AB_141373</ext-link>) were used to detect immune complexes in co-staining experiments. These sections were counterstained with DAPI and immunofluorescence was examined using a Leica SP2 confocal microscope.</p></sec><sec id="s4-12"><title>Immunoblot analysis</title><p>Cell lysates were prepared using Triton lysis buffer (20 mM Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 μg/mL of aprotinin and leupeptin). Extracts (30 µg) were examined by immunoblot analysis by probing with antibodies to phospho-ERK (Cell Signaling Technology Cat# 9101 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331646">AB_331646</ext-link>), ERK2 (Santa Cruz Biotechnology Cat# sc-1647 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_627547">AB_627547</ext-link>), phospho-JNK (Cell Signaling Technology Cat# 9255 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2307321">AB_2307321</ext-link>), JNK (R and D Systems Cat# AF1387 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2140743">AB_2140743</ext-link>), p38 (Cell Signaling Technology Cat# 9212 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_330713">AB_330713</ext-link>), phospho-p38 (Cell Signaling Technology Cat# 9211 also 9211L, 9211S RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331641">AB_331641</ext-link>), phospho-JUN (S63) (Cell Signaling Technology Cat# 9261L RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2130159">AB_2130159</ext-link>), JUN (Santa Cruz Biotechnology Cat# sc-1694 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_631263">AB_631263</ext-link>), p-AKT (T308) (Cell Signaling Technology Cat# 5106S RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_836861">AB_836861</ext-link>), p-AKT (S473) (Cell Signaling Technology Cat# 9271 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_329825">AB_329825</ext-link>), AKT (Cell Signaling Technology Cat# 9272 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_329827">AB_329827</ext-link>), and α-Tubulin (Millipore-Sigma Cat# T5168 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_477579">AB_477579</ext-link>). IRDye 680LT conjugated-donkey anti-mouse IgG antibody (LI-COR Biosciences Cat# 926–68022 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10715072">AB_10715072</ext-link>) and IRDye 800CW conjugated-goat anti-rabbit IgG (LI-COR Biosciences Cat# 926–32211 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_621843">AB_621843</ext-link>) were used to detect and quantitate immune complexes with the Odyssey infrared imaging system (LI-COR Biosciences).</p></sec><sec id="s4-13"><title>Exome sequencing</title><p>Genomic DNA was isolated from cancer cell lines using the DNEasy kit, including RNase treatment (Qiagen). For each genotype, a control sample was generated by isolating genomic DNA from mammary glands of a virgin mouse of the same genotype. Whole exome sequencing libraries were prepared using the Agilent SureSelect XT library preparation kit. DNA (OD260/280 1.7–2.0 and OD260/230 &gt; 2.0) was sheared using a Covaris LE220. End-repaired, adenylated DNA fragments were ligated to Illumina sequencing adapters and amplified by PCR. Exome capture was performed using the Agilent SureSelect Mouse All Exon (50 mb) capture probe set; captured exome libraries were enriched by PCR. Final libraries were quantified using the KAPA Library Quantification Kit (KAPA Biosystems), Qubit Fluorometer (Life Technologies) and Agilent 2100 BioAnalyzer, and were sequenced on an Illumina HiSeq2500 machine using 2 × 125 bp cycles. Single nucleotide variants were reported as the union of SNVs called by muTect (<xref ref-type="bibr" rid="bib13">Cibulskis et al., 2013</xref>), Strelka (<xref ref-type="bibr" rid="bib53">Saunders et al., 2012</xref>), and LoFreq (<xref ref-type="bibr" rid="bib75">Wilm et al., 2012</xref>) and indels were reported as the union of indels called by Strelka, somatic versions of Pindel (<xref ref-type="bibr" rid="bib77">Ye et al., 2009</xref>) and Scalpel (<xref ref-type="bibr" rid="bib43">Narzisi et al., 2014</xref>). ExomeCNV was run with default settings using mm10 reference to generate copy-number calls (<xref ref-type="bibr" rid="bib52">Sathirapongsasuti et al., 2011</xref>). The segmentation and log<sub>2</sub> ratios from ExomeCNV output were used to identify amplified, deleted and copy-neutral regions. Log<sub>2</sub> thresholds of &gt;0.2 and &lt;−0.2 were used to label a segment as amplified or deleted, respectively, and the segments were visualized (<xref ref-type="bibr" rid="bib32">Krzywinski et al., 2009</xref>). Bedtools (<xref ref-type="bibr" rid="bib49">Quinlan and Hall, 2010</xref>) was run to identify genes overlapping copy-number segments.</p></sec><sec id="s4-14"><title>Analysis of mRNA expression</title><p>Cellular RNA was isolated using the RNeasy kit with DNase treatment (Qiagen) and RNA quality (RIN &gt;9) was confirmed using the Bioanalyzer 2100 system (Agilent Technologies). Libraries were constructed according to the manufacturer’s instructions (Illumina). Two to three libraries were analyzed for each condition. Single-end sequencing with reads of 40 bp reads (for JNK<sup>WT</sup> and JNK<sup>KO</sup>) was performed on an Illumina HiSeq 2000 platform and paired-end sequencing with 150 bp reads (for MEC and ME<sup>KO</sup>) was performed on an Illumina NextSeq500 platform (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Poor quality reads, adapter sequences, and reads less than 40 bp were removed using Trimmomatic (version 0.36) (<xref ref-type="bibr" rid="bib5">Bolger et al., 2014</xref>). First, the MEC and ME<sup>KO</sup> biological groups were analyzed (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Second, to adequately compare the four biological groups (MEC, ME<sup>KO</sup>, JNK<sup>WT</sup>, and JNK<sup>KO</sup>), seqtk was used to sample sequences averaging 40 million single-end reads per sample (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) (<xref ref-type="bibr" rid="bib37">Li, 2017</xref>). Reads were aligned to the mouse genome mm10 using Bowtie2 (v 2–2.1.0) (<xref ref-type="bibr" rid="bib34">Langmead and Salzberg, 2012</xref>) and Tophat2 (v 2.0.14) (<xref ref-type="bibr" rid="bib31">Kim et al., 2013</xref>). Samtools (version 0.0.19) (<xref ref-type="bibr" rid="bib36">Li et al., 2009</xref>) and IGV (version 2.3.60) (<xref ref-type="bibr" rid="bib61">Thorvaldsdóttir et al., 2013</xref>) were used for indexing the alignment files and viewing the aligned reads respectively. Cufflinks (v 2.2.1) (<xref ref-type="bibr" rid="bib64">Trapnell et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Trapnell et al., 2010</xref>) was used to quantitate gene expression as fragments per kilobase of exon model per million mapped fragments (FPKM); differential expression was identified using the Cufflinks tools, Cuffmerge and Cuffdiff. Cummerbund version 2.4.1 (<xref ref-type="bibr" rid="bib64">Trapnell et al., 2012</xref>) was used to assess replicate concordance. The complex heatmap package version 1.12.0 (<xref ref-type="bibr" rid="bib23">Gu et al., 2016</xref>) was used to generate heatmaps of differentially expressed (q &lt; 0.05, |log<sub>2</sub> Fold Change| &gt; 0.75) genes.</p><p>Pathway over-representation analysis was performed on differentially expressed genes using the WEB-based GEne SeT AnaLysis Toolkit (Webgestalt) (<xref ref-type="bibr" rid="bib70">Wang et al., 2013</xref>) with the KEGG database. This analysis was also performed with gene set enrichment analysis (GSEA) software (version 3.0) (<xref ref-type="bibr" rid="bib59">Subramanian et al., 2005</xref>) using ranked genes (sign of the log<sub>2</sub> fold change times the log<sub>10</sub> <italic>p</italic>-value) (<xref ref-type="bibr" rid="bib47">Plaisier et al., 2010</xref>) and the MSigDB gene sets: HALLMARK_KRAS_SIGNALING_UP (M5953); and HALLMARK_DNA_REPAIR (M5898). The gene symbols for the mouse equivalents were used in the gene set enrichment analysis using Ensembl BioMart v87 (<xref ref-type="bibr" rid="bib57">Smedley et al., 2015</xref>).</p><p>Ingenuity Pathway Analysis (Qiagen) was used to predict pathway activation based on differentially expressed genes. The top 100 pathways ranked by score (the sum across tumor genotypes of -log<sub>10</sub> p-value calculated by Fisher’s exact test) were identified. Treeview (Java) (<xref ref-type="bibr" rid="bib50">Saldanha, 2004</xref>) was used to make heatmaps showing pathway activation z-scores.</p><p>The expression of mRNA was also determined by RT-PCR using a Quantstudio 12K Flex machine (Thermo Fisher Scientific). TaqMan assays were used to quantify the expression of <italic>Bmi1</italic> (Mm03053308_g1), <italic>Pou5f1</italic> (Mm03053917_g1), and <italic>Nanog</italic> (Mm02019550_s1). Relative expression was normalized to the expression of <italic>18S</italic> RNA in each sample using Taqman assays (catalog number 4308329; Thermo Fisher Scientific).</p></sec><sec id="s4-15"><title>Statistical analysis</title><p>Data are presented as the mean and standard error. Statistical analysis was performed using GraphPad Prism version 7 (GraphPad Software). ANOVA with Bonferroni’s test was used to determine significance with an assumed confidence interval of 95%. Two-tailed, unpaired t-test with Welch’s correction was used for pairwise comparisons. Fisher’s Exact Test was used to determine differences in tumor or MIN incidence. Kaplan-Meier analysis of mammary tumor-free survival was performed using the log-rank test. Statistical significance was defined as p&lt;0.05.</p></sec><sec id="s4-16"><title>Data availability</title><p>Raw data are presented in the Source Data file. Flow cytometry data have been deposited with FlowRepository (Repository ID:FR-FCM-ZYEV). The RNA-seq data have been deposited with NCBI; GEO accession numbers GSE100581 and GSE92560. The exome sequence data were deposited with NCBI; SRA accession number SRP117075.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the New York Genome Center and the MIT BioMicro Center for assistance with sequence analysis, Armanda Roy for expert technical assistance, and Kathy Gemme for administrative assistance. RJD is an investigator of the Howard Hughes Medical Institute. The authors declare no competing financial interests.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Formal analysis, Supervision, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#A-1032) of the University of Massachusetts Medical School.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.36389.032</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-36389-transrepform-v1.docx"/></supplementary-material><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data have been deposited with NCBI. Flow cytometry data have been deposited with Flow Repository. All other data are provided as source data files published with this manuscript.</p><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataset2" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100581" source-id-type="uri"><collab collab-type="author">Girnius</collab><collab collab-type="author">Edwards</collab><collab collab-type="author">Garlick</collab><collab collab-type="author">Davis</collab><year>2018</year><source>The cJun NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation</source><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100581">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100581</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE100581)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset3" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92560" source-id-type="uri"><collab collab-type="author">Girnius</collab><collab collab-type="author">Edwards</collab><collab collab-type="author">Garlick</collab><collab collab-type="author">Davis</collab><year>2018</year><source>The cJun NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation</source><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92560">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92560</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE92560)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset4" source-id="http://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?study=SRP117075" source-id-type="uri"><collab collab-type="author">Girnius</collab><collab collab-type="author">Edwards</collab><collab collab-type="author">Garlick</collab><collab collab-type="author">Davis</collab><year>2018</year><source>The cJun NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation</source><ext-link ext-link-type="uri" xlink:href="http://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?study=SRP117075">http://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?study=SRP117075</ext-link><comment>Publicly available at the NCBI Sequence Read Archive (accession no. SRP117075)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset5" source-id="http://flowrepository.org/id/FR-FCM-ZYEV" source-id-type="uri"><collab collab-type="author">Girnius</collab><collab collab-type="author">Edwards</collab><collab collab-type="author">Garlick</collab><collab collab-type="author">Davis</collab><year>2018</year><source>The cJun NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation</source><ext-link ext-link-type="uri" xlink:href="http://flowrepository.org/id/FR-FCM-ZYEV">http://flowrepository.org/id/FR-FCM-ZYEV</ext-link><comment>Publicly available at FlowRepository (accession no. FR-FCM-ZYEV)</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afghahi</surname> <given-names>A</given-names></name><name><surname>Kurian</surname> <given-names>AW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The changing landscape of genetic testing for inherited breast cancer predisposition</article-title><source>Current Treatment Options in Oncology</source><volume>18</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1007/s11864-017-0468-y</pub-id><pub-id pub-id-type="pmid">28439798</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babaei</surname> <given-names>S</given-names></name><name><surname>Hulsman</surname> <given-names>M</given-names></name><name><surname>Reinders</surname> <given-names>M</given-names></name><name><surname>de Ridder</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Detecting recurrent gene mutation in interaction network context using multi-scale graph diffusion</article-title><source>BMC Bioinformatics</source><volume>14</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-14-29</pub-id><pub-id pub-id-type="pmid">23343428</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerji</surname> <given-names>S</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Rangel-Escareno</surname> <given-names>C</given-names></name><name><surname>Brown</surname> <given-names>KK</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Frederick</surname> <given-names>AM</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Sivachenko</surname> <given-names>AY</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Zou</surname> <given-names>L</given-names></name><name><surname>Cortes</surname> <given-names>ML</given-names></name><name><surname>Fernandez-Lopez</surname> <given-names>JC</given-names></name><name><surname>Peng</surname> <given-names>S</given-names></name><name><surname>Ardlie</surname> <given-names>KG</given-names></name><name><surname>Auclair</surname> <given-names>D</given-names></name><name><surname>Bautista-Piña</surname> <given-names>V</given-names></name><name><surname>Duke</surname> <given-names>F</given-names></name><name><surname>Francis</surname> <given-names>J</given-names></name><name><surname>Jung</surname> <given-names>J</given-names></name><name><surname>Maffuz-Aziz</surname> <given-names>A</given-names></name><name><surname>Onofrio</surname> <given-names>RC</given-names></name><name><surname>Parkin</surname> <given-names>M</given-names></name><name><surname>Pho</surname> <given-names>NH</given-names></name><name><surname>Quintanar-Jurado</surname> <given-names>V</given-names></name><name><surname>Ramos</surname> <given-names>AH</given-names></name><name><surname>Rebollar-Vega</surname> <given-names>R</given-names></name><name><surname>Rodriguez-Cuevas</surname> <given-names>S</given-names></name><name><surname>Romero-Cordoba</surname> <given-names>SL</given-names></name><name><surname>Schumacher</surname> <given-names>SE</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Thompson</surname> <given-names>KM</given-names></name><name><surname>Uribe-Figueroa</surname> <given-names>L</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Polyak</surname> <given-names>K</given-names></name><name><surname>Sgroi</surname> <given-names>DC</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Jimenez-Sanchez</surname> <given-names>G</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Melendez-Zajgla</surname> <given-names>J</given-names></name><name><surname>Toker</surname> <given-names>A</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Hidalgo-Miranda</surname> <given-names>A</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sequence analysis of mutations and translocations across breast cancer subtypes</article-title><source>Nature</source><volume>486</volume><fpage>405</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1038/nature11154</pub-id><pub-id pub-id-type="pmid">22722202</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname> <given-names>AH</given-names></name><name><surname>Brooks</surname> <given-names>AN</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Shrestha</surname> <given-names>Y</given-names></name><name><surname>Chouinard</surname> <given-names>C</given-names></name><name><surname>Piccioni</surname> <given-names>F</given-names></name><name><surname>Bagul</surname> <given-names>M</given-names></name><name><surname>Kamburov</surname> <given-names>A</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Hogstrom</surname> <given-names>L</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Pantel</surname> <given-names>S</given-names></name><name><surname>Sakai</surname> <given-names>R</given-names></name><name><surname>Watson</surname> <given-names>J</given-names></name><name><surname>Kaplan</surname> <given-names>N</given-names></name><name><surname>Campbell</surname> <given-names>JD</given-names></name><name><surname>Singh</surname> <given-names>S</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Narayan</surname> <given-names>R</given-names></name><name><surname>Natoli</surname> <given-names>T</given-names></name><name><surname>Lahr</surname> <given-names>DL</given-names></name><name><surname>Tirosh</surname> <given-names>I</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Wong</surname> <given-names>B</given-names></name><name><surname>Doench</surname> <given-names>J</given-names></name><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>High-throughput phenotyping of lung Cancer somatic mutations</article-title><source>Cancer Cell</source><volume>30</volume><fpage>214</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.06.022</pub-id><pub-id pub-id-type="pmid">27478040</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname> <given-names>AM</given-names></name><name><surname>Lohse</surname> <given-names>M</given-names></name><name><surname>Usadel</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calses</surname> <given-names>PC</given-names></name><name><surname>Dhillon</surname> <given-names>KK</given-names></name><name><surname>Tucker</surname> <given-names>N</given-names></name><name><surname>Chi</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>JW</given-names></name><name><surname>Kawasumi</surname> <given-names>M</given-names></name><name><surname>Nghiem</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Clurman</surname> <given-names>BE</given-names></name><name><surname>Jacquemont</surname> <given-names>C</given-names></name><name><surname>Gafken</surname> <given-names>PR</given-names></name><name><surname>Sugasawa</surname> <given-names>K</given-names></name><name><surname>Saijo</surname> <given-names>M</given-names></name><name><surname>Taniguchi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>DGCR8 mediates repair of UV-Induced DNA damage independently of RNA processing</article-title><source>Cell Reports</source><volume>19</volume><fpage>162</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.03.021</pub-id><pub-id pub-id-type="pmid">28380355</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Network</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Comprehensive molecular portraits of human breast tumours</article-title><source>Nature</source><volume>490</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nature11412</pub-id><pub-id pub-id-type="pmid">23000897</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardiff</surname> <given-names>RD</given-names></name><name><surname>Anver</surname> <given-names>MR</given-names></name><name><surname>Gusterson</surname> <given-names>BA</given-names></name><name><surname>Hennighausen</surname> <given-names>L</given-names></name><name><surname>Jensen</surname> <given-names>RA</given-names></name><name><surname>Merino</surname> <given-names>MJ</given-names></name><name><surname>Rehm</surname> <given-names>S</given-names></name><name><surname>Russo</surname> <given-names>J</given-names></name><name><surname>Tavassoli</surname> <given-names>FA</given-names></name><name><surname>Wakefield</surname> <given-names>LM</given-names></name><name><surname>Ward</surname> <given-names>JM</given-names></name><name><surname>Green</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting</article-title><source>Oncogene</source><volume>19</volume><fpage>968</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203277</pub-id><pub-id pub-id-type="pmid">10713680</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Isik</surname> <given-names>L</given-names></name><name><surname>Tyekucheva</surname> <given-names>S</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Karchin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations</article-title><source>Cancer Research</source><volume>69</volume><fpage>6660</fpage><lpage>6667</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1133</pub-id><pub-id pub-id-type="pmid">19654296</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cellurale</surname> <given-names>C</given-names></name><name><surname>Girnius</surname> <given-names>N</given-names></name><name><surname>Jiang</surname> <given-names>F</given-names></name><name><surname>Cavanagh-Kyros</surname> <given-names>J</given-names></name><name><surname>Lu</surname> <given-names>S</given-names></name><name><surname>Garlick</surname> <given-names>DS</given-names></name><name><surname>Mercurio</surname> <given-names>AM</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of JNK in mammary gland development and breast cancer</article-title><source>Cancer Research</source><volume>72</volume><fpage>472</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1628</pub-id><pub-id pub-id-type="pmid">22127926</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cellurale</surname> <given-names>C</given-names></name><name><surname>Weston</surname> <given-names>CR</given-names></name><name><surname>Reilly</surname> <given-names>J</given-names></name><name><surname>Garlick</surname> <given-names>DS</given-names></name><name><surname>Jerry</surname> <given-names>DJ</given-names></name><name><surname>Sluss</surname> <given-names>HK</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Role of JNK in a Trp53-dependent mouse model of breast cancer</article-title><source>PLoS One</source><volume>5</volume><elocation-id>e12469</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012469</pub-id><pub-id pub-id-type="pmid">20814571</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname> <given-names>E</given-names></name><name><surname>Demir</surname> <given-names>E</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Taylor</surname> <given-names>BS</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Automated network analysis identifies core pathways in glioblastoma</article-title><source>PLoS One</source><volume>5</volume><elocation-id>e8918</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0008918</pub-id><pub-id pub-id-type="pmid">20169195</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Sivachenko</surname> <given-names>A</given-names></name><name><surname>Jaffe</surname> <given-names>D</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title><source>Nature Biotechnology</source><volume>31</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1038/nbt.2514</pub-id><pub-id pub-id-type="pmid">23396013</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciriello</surname> <given-names>G</given-names></name><name><surname>Gatza</surname> <given-names>ML</given-names></name><name><surname>Beck</surname> <given-names>AH</given-names></name><name><surname>Wilkerson</surname> <given-names>MD</given-names></name><name><surname>Rhie</surname> <given-names>SK</given-names></name><name><surname>Pastore</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>McLellan</surname> <given-names>M</given-names></name><name><surname>Yau</surname> <given-names>C</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Bowlby</surname> <given-names>R</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Hayat</surname> <given-names>S</given-names></name><name><surname>Fieldhouse</surname> <given-names>R</given-names></name><name><surname>Lester</surname> <given-names>SC</given-names></name><name><surname>Tse</surname> <given-names>GM</given-names></name><name><surname>Factor</surname> <given-names>RE</given-names></name><name><surname>Collins</surname> <given-names>LC</given-names></name><name><surname>Allison</surname> <given-names>KH</given-names></name><name><surname>Chen</surname> <given-names>YY</given-names></name><name><surname>Jensen</surname> <given-names>K</given-names></name><name><surname>Johnson</surname> <given-names>NB</given-names></name><name><surname>Oesterreich</surname> <given-names>S</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Robertson</surname> <given-names>G</given-names></name><name><surname>Benz</surname> <given-names>C</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>King</surname> <given-names>TA</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><collab>TCGA Research Network</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Comprehensive molecular portraits of invasive lobular breast Cancer</article-title><source>Cell</source><volume>163</volume><fpage>506</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.09.033</pub-id><pub-id pub-id-type="pmid">26451490</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname> <given-names>M</given-names></name><name><surname>Jiang</surname> <given-names>F</given-names></name><name><surname>Sluss</surname> <given-names>HK</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Shokat</surname> <given-names>KM</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Suppression of p53-dependent senescence by the JNK signal transduction pathway</article-title><source>PNAS</source><volume>104</volume><fpage>15759</fpage><lpage>15764</lpage><pub-id pub-id-type="doi">10.1073/pnas.0707782104</pub-id><pub-id pub-id-type="pmid">17893331</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Signal transduction by the JNK group of MAP kinases</article-title><source>Cell</source><volume>103</volume><fpage>239</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00116-1</pub-id><pub-id pub-id-type="pmid">11057897</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Barco Barrantes</surname> <given-names>I</given-names></name><name><surname>Stephan-Otto Attolini</surname> <given-names>C</given-names></name><name><surname>Slobodnyuk</surname> <given-names>K</given-names></name><name><surname>Igea</surname> <given-names>A</given-names></name><name><surname>Gregorio</surname> <given-names>S</given-names></name><name><surname>Gawrzak</surname> <given-names>S</given-names></name><name><surname>Gomis</surname> <given-names>RR</given-names></name><name><surname>Nebreda</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regulation of mammary luminal cell fate and tumorigenesis by p38α</article-title><source>Stem Cell Reports</source><volume>10</volume><fpage>257</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.11.021</pub-id><pub-id pub-id-type="pmid">29290625</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname> <given-names>MJ</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Shen</surname> <given-names>D</given-names></name><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>Suman</surname> <given-names>VJ</given-names></name><name><surname>Wallis</surname> <given-names>JW</given-names></name><name><surname>Van Tine</surname> <given-names>BA</given-names></name><name><surname>Hoog</surname> <given-names>J</given-names></name><name><surname>Goiffon</surname> <given-names>RJ</given-names></name><name><surname>Goldstein</surname> <given-names>TC</given-names></name><name><surname>Ng</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Crowder</surname> <given-names>R</given-names></name><name><surname>Snider</surname> <given-names>J</given-names></name><name><surname>Ballman</surname> <given-names>K</given-names></name><name><surname>Weber</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Koboldt</surname> <given-names>DC</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Schierding</surname> <given-names>WS</given-names></name><name><surname>McMichael</surname> <given-names>JF</given-names></name><name><surname>Miller</surname> <given-names>CA</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Harris</surname> <given-names>CC</given-names></name><name><surname>McLellan</surname> <given-names>MD</given-names></name><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>DeSchryver</surname> <given-names>K</given-names></name><name><surname>Allred</surname> <given-names>DC</given-names></name><name><surname>Esserman</surname> <given-names>L</given-names></name><name><surname>Unzeitig</surname> <given-names>G</given-names></name><name><surname>Margenthaler</surname> <given-names>J</given-names></name><name><surname>Babiera</surname> <given-names>GV</given-names></name><name><surname>Marcom</surname> <given-names>PK</given-names></name><name><surname>Guenther</surname> <given-names>JM</given-names></name><name><surname>Leitch</surname> <given-names>M</given-names></name><name><surname>Hunt</surname> <given-names>K</given-names></name><name><surname>Olson</surname> <given-names>J</given-names></name><name><surname>Tao</surname> <given-names>Y</given-names></name><name><surname>Maher</surname> <given-names>CA</given-names></name><name><surname>Fulton</surname> <given-names>LL</given-names></name><name><surname>Fulton</surname> <given-names>RS</given-names></name><name><surname>Harrison</surname> <given-names>M</given-names></name><name><surname>Oberkfell</surname> <given-names>B</given-names></name><name><surname>Du</surname> <given-names>F</given-names></name><name><surname>Demeter</surname> <given-names>R</given-names></name><name><surname>Vickery</surname> <given-names>TL</given-names></name><name><surname>Elhammali</surname> <given-names>A</given-names></name><name><surname>Piwnica-Worms</surname> <given-names>H</given-names></name><name><surname>McDonald</surname> <given-names>S</given-names></name><name><surname>Watson</surname> <given-names>M</given-names></name><name><surname>Dooling</surname> <given-names>DJ</given-names></name><name><surname>Ota</surname> <given-names>D</given-names></name><name><surname>Chang</surname> <given-names>LW</given-names></name><name><surname>Bose</surname> <given-names>R</given-names></name><name><surname>Ley</surname> <given-names>TJ</given-names></name><name><surname>Piwnica-Worms</surname> <given-names>D</given-names></name><name><surname>Stuart</surname> <given-names>JM</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Whole-genome analysis informs breast cancer response to aromatase inhibition</article-title><source>Nature</source><volume>486</volume><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/nature11143</pub-id><pub-id pub-id-type="pmid">22722193</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lessons from the cancer genome</article-title><source>Cell</source><volume>153</volume><fpage>17</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.002</pub-id><pub-id pub-id-type="pmid">23540688</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gawrzak</surname> <given-names>S</given-names></name><name><surname>Rinaldi</surname> <given-names>L</given-names></name><name><surname>Gregorio</surname> <given-names>S</given-names></name><name><surname>Arenas</surname> <given-names>EJ</given-names></name><name><surname>Salvador</surname> <given-names>F</given-names></name><name><surname>Urosevic</surname> <given-names>J</given-names></name><name><surname>Figueras-Puig</surname> <given-names>C</given-names></name><name><surname>Rojo</surname> <given-names>F</given-names></name><name><surname>Del Barco Barrantes</surname> <given-names>I</given-names></name><name><surname>Cejalvo</surname> <given-names>JM</given-names></name><name><surname>Palafox</surname> <given-names>M</given-names></name><name><surname>Guiu</surname> <given-names>M</given-names></name><name><surname>Berenguer-Llergo</surname> <given-names>A</given-names></name><name><surname>Symeonidi</surname> <given-names>A</given-names></name><name><surname>Bellmunt</surname> <given-names>A</given-names></name><name><surname>Kalafatovic</surname> <given-names>D</given-names></name><name><surname>Arnal-Estapé</surname> <given-names>A</given-names></name><name><surname>Fernández</surname> <given-names>E</given-names></name><name><surname>Müllauer</surname> <given-names>B</given-names></name><name><surname>Groeneveld</surname> <given-names>R</given-names></name><name><surname>Slobodnyuk</surname> <given-names>K</given-names></name><name><surname>Stephan-Otto Attolini</surname> <given-names>C</given-names></name><name><surname>Saura</surname> <given-names>C</given-names></name><name><surname>Arribas</surname> <given-names>J</given-names></name><name><surname>Cortes</surname> <given-names>J</given-names></name><name><surname>Rovira</surname> <given-names>A</given-names></name><name><surname>Muñoz</surname> <given-names>M</given-names></name><name><surname>Lluch</surname> <given-names>A</given-names></name><name><surname>Serra</surname> <given-names>V</given-names></name><name><surname>Albanell</surname> <given-names>J</given-names></name><name><surname>Prat</surname> <given-names>A</given-names></name><name><surname>Nebreda</surname> <given-names>AR</given-names></name><name><surname>Benitah</surname> <given-names>SA</given-names></name><name><surname>Gomis</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MSK1 regulates luminal cell differentiation and metastatic dormancy in ER<sup>+</sup> breast cancer</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/s41556-017-0021-z</pub-id><pub-id pub-id-type="pmid">29358704</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girnius</surname> <given-names>N</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>JNK promotes epithelial cell anoikis by transcriptional and Post-translational regulation of BH3-Only proteins</article-title><source>Cell Reports</source><volume>21</volume><fpage>1910</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.10.067</pub-id><pub-id pub-id-type="pmid">29141222</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girnius</surname> <given-names>N</given-names></name><name><surname>Edwards</surname> <given-names>YJK</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The cJUN NH<sub>2</sub>-terminal kinase (JNK) pathway contributes to mouse mammary gland remodeling during involution</article-title><source>Cell Death &amp; Differentiation</source><pub-id pub-id-type="doi">10.1038/s41418-018-0081-z</pub-id><pub-id pub-id-type="pmid">29511338</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>Z</given-names></name><name><surname>Eils</surname> <given-names>R</given-names></name><name><surname>Schlesner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title><source>Bioinformatics</source><volume>32</volume><fpage>2847</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw313</pub-id><pub-id pub-id-type="pmid">27207943</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Pylayeva</surname> <given-names>Y</given-names></name><name><surname>Pepe</surname> <given-names>A</given-names></name><name><surname>Yoshioka</surname> <given-names>T</given-names></name><name><surname>Muller</surname> <given-names>WJ</given-names></name><name><surname>Inghirami</surname> <given-names>G</given-names></name><name><surname>Giancotti</surname> <given-names>FG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis</article-title><source>Cell</source><volume>126</volume><fpage>489</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.05.047</pub-id><pub-id pub-id-type="pmid">16901783</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halaoui</surname> <given-names>R</given-names></name><name><surname>Rejon</surname> <given-names>C</given-names></name><name><surname>Chatterjee</surname> <given-names>SJ</given-names></name><name><surname>Szymborski</surname> <given-names>J</given-names></name><name><surname>Meterissian</surname> <given-names>S</given-names></name><name><surname>Muller</surname> <given-names>WJ</given-names></name><name><surname>Omeroglu</surname> <given-names>A</given-names></name><name><surname>McCaffrey</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Progressive polarity loss and luminal collapse disrupt tissue organization in carcinoma</article-title><source>Genes &amp; Development</source><volume>31</volume><fpage>1573</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1101/gad.300566.117</pub-id><pub-id pub-id-type="pmid">28887414</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>MS</given-names></name><name><surname>Jung</surname> <given-names>DY</given-names></name><name><surname>Morel</surname> <given-names>C</given-names></name><name><surname>Lakhani</surname> <given-names>SA</given-names></name><name><surname>Kim</surname> <given-names>JK</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation</article-title><source>Science</source><volume>339</volume><fpage>218</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1126/science.1227568</pub-id><pub-id pub-id-type="pmid">23223452</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname> <given-names>D</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname> <given-names>KL</given-names></name><name><surname>Sosa</surname> <given-names>MS</given-names></name><name><surname>Entenberg</surname> <given-names>D</given-names></name><name><surname>Hosseini</surname> <given-names>H</given-names></name><name><surname>Cheung</surname> <given-names>JF</given-names></name><name><surname>Nobre</surname> <given-names>R</given-names></name><name><surname>Avivar-Valderas</surname> <given-names>A</given-names></name><name><surname>Nagi</surname> <given-names>C</given-names></name><name><surname>Girnius</surname> <given-names>N</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name><name><surname>Farias</surname> <given-names>EF</given-names></name><name><surname>Condeelis</surname> <given-names>J</given-names></name><name><surname>Klein</surname> <given-names>CA</given-names></name><name><surname>Aguirre-Ghiso</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanism of early dissemination and metastasis in Her2<sup>+</sup> mammary cancer</article-title><source>Nature</source><volume>540</volume><fpage>588</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/nature20609</pub-id><pub-id pub-id-type="pmid">27974798</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminker</surname> <given-names>JS</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Watanabe</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CanPredict: a computational tool for predicting cancer-associated missense mutations</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>W595</fpage><lpage>W598</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm405</pub-id><pub-id pub-id-type="pmid">17537827</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kan</surname> <given-names>Z</given-names></name><name><surname>Jaiswal</surname> <given-names>BS</given-names></name><name><surname>Stinson</surname> <given-names>J</given-names></name><name><surname>Janakiraman</surname> <given-names>V</given-names></name><name><surname>Bhatt</surname> <given-names>D</given-names></name><name><surname>Stern</surname> <given-names>HM</given-names></name><name><surname>Yue</surname> <given-names>P</given-names></name><name><surname>Haverty</surname> <given-names>PM</given-names></name><name><surname>Bourgon</surname> <given-names>R</given-names></name><name><surname>Zheng</surname> <given-names>J</given-names></name><name><surname>Moorhead</surname> <given-names>M</given-names></name><name><surname>Chaudhuri</surname> <given-names>S</given-names></name><name><surname>Tomsho</surname> <given-names>LP</given-names></name><name><surname>Peters</surname> <given-names>BA</given-names></name><name><surname>Pujara</surname> <given-names>K</given-names></name><name><surname>Cordes</surname> <given-names>S</given-names></name><name><surname>Davis</surname> <given-names>DP</given-names></name><name><surname>Carlton</surname> <given-names>VE</given-names></name><name><surname>Yuan</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Eigenbrot</surname> <given-names>C</given-names></name><name><surname>Kaminker</surname> <given-names>JS</given-names></name><name><surname>Eberhard</surname> <given-names>DA</given-names></name><name><surname>Waring</surname> <given-names>P</given-names></name><name><surname>Schuster</surname> <given-names>SC</given-names></name><name><surname>Modrusan</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Stokoe</surname> <given-names>D</given-names></name><name><surname>de Sauvage</surname> <given-names>FJ</given-names></name><name><surname>Faham</surname> <given-names>M</given-names></name><name><surname>Seshagiri</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Diverse somatic mutation patterns and pathway alterations in human cancers</article-title><source>Nature</source><volume>466</volume><fpage>869</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1038/nature09208</pub-id><pub-id pub-id-type="pmid">20668451</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Pertea</surname> <given-names>G</given-names></name><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Kelley</surname> <given-names>R</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions</article-title><source>Genome Biology</source><volume>14</volume><elocation-id>R36</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2013-14-4-r36</pub-id><pub-id pub-id-type="pmid">23618408</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krzywinski</surname> <given-names>M</given-names></name><name><surname>Schein</surname> <given-names>J</given-names></name><name><surname>Birol</surname> <given-names>I</given-names></name><name><surname>Connors</surname> <given-names>J</given-names></name><name><surname>Gascoyne</surname> <given-names>R</given-names></name><name><surname>Horsman</surname> <given-names>D</given-names></name><name><surname>Jones</surname> <given-names>SJ</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Circos: an information aesthetic for comparative genomics</article-title><source>Genome Research</source><volume>19</volume><fpage>1639</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1101/gr.092759.109</pub-id><pub-id pub-id-type="pmid">19541911</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname> <given-names>JA</given-names></name><name><surname>Ventura</surname> <given-names>JJ</given-names></name><name><surname>Hess</surname> <given-names>P</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>JunD mediates survival signaling by the JNK signal transduction pathway</article-title><source>Molecular Cell</source><volume>11</volume><fpage>1479</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00203-X</pub-id><pub-id pub-id-type="pmid">12820962</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname> <given-names>B</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname> <given-names>CT</given-names></name><name><surname>Brugge</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Outgrowth of single oncogene-expressing cells from suppressive epithelial environments</article-title><source>Nature</source><volume>482</volume><fpage>410</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1038/nature10826</pub-id><pub-id pub-id-type="pmid">22318515</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Handsaker</surname> <given-names>B</given-names></name><name><surname>Wysoker</surname> <given-names>A</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Ruan</surname> <given-names>J</given-names></name><name><surname>Homer</surname> <given-names>N</given-names></name><name><surname>Marth</surname> <given-names>G</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><year iso-8601-date="2009">2009</year><article-title>The sequence alignment/map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Seqtk - Toolkit for processing sequences in FASTA/Q formats.</data-title><ext-link ext-link-type="uri" xlink:href="https://github.com/lh3/seqtk">https://github.com/lh3/seqtk</ext-link></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Gan</surname> <given-names>CM</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Jones</surname> <given-names>S</given-names></name><name><surname>Sjöblom</surname> <given-names>T</given-names></name><name><surname>Wood</surname> <given-names>LD</given-names></name><name><surname>Parsons</surname> <given-names>DW</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Parmigiani</surname> <given-names>G</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A multidimensional analysis of genes mutated in breast and colorectal cancers</article-title><source>Genome Research</source><volume>17</volume><fpage>1304</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1101/gr.6431107</pub-id><pub-id pub-id-type="pmid">17693572</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>F</given-names></name><name><surname>Cho</surname> <given-names>YY</given-names></name><name><surname>Tang</surname> <given-names>F</given-names></name><name><surname>Zykova</surname> <given-names>T</given-names></name><name><surname>Ma</surname> <given-names>WY</given-names></name><name><surname>Bode</surname> <given-names>AM</given-names></name><name><surname>Dong</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3</article-title><source>Molecular Cell</source><volume>23</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.05.023</pub-id><pub-id pub-id-type="pmid">16818236</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcotte</surname> <given-names>R</given-names></name><name><surname>Sayad</surname> <given-names>A</given-names></name><name><surname>Brown</surname> <given-names>KR</given-names></name><name><surname>Sanchez-Garcia</surname> <given-names>F</given-names></name><name><surname>Reimand</surname> <given-names>J</given-names></name><name><surname>Haider</surname> <given-names>M</given-names></name><name><surname>Virtanen</surname> <given-names>C</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Bader</surname> <given-names>GD</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Pe'er</surname> <given-names>D</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name><name><surname>Neel</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional genomic landscape of human breast Cancer drivers, vulnerabilities, and resistance</article-title><source>Cell</source><volume>164</volume><fpage>293</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.062</pub-id><pub-id pub-id-type="pmid">26771497</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname> <given-names>S</given-names></name><name><surname>Vooijs</surname> <given-names>M</given-names></name><name><surname>van Der Gulden</surname> <given-names>H</given-names></name><name><surname>Jonkers</surname> <given-names>J</given-names></name><name><surname>Berns</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of rb in the external granular layer cells of the cerebellum</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>994</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">10783170</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzumdar</surname> <given-names>MD</given-names></name><name><surname>Tasic</surname> <given-names>B</given-names></name><name><surname>Miyamichi</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Luo</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A global double-fluorescent Cre reporter mouse</article-title><source>Genesis</source><volume>45</volume><fpage>593</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1002/dvg.20335</pub-id><pub-id pub-id-type="pmid">17868096</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narzisi</surname> <given-names>G</given-names></name><name><surname>O'Rawe</surname> <given-names>JA</given-names></name><name><surname>Iossifov</surname> <given-names>I</given-names></name><name><surname>Fang</surname> <given-names>H</given-names></name><name><surname>Lee</surname> <given-names>YH</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Lyon</surname> <given-names>GJ</given-names></name><name><surname>Wigler</surname> <given-names>M</given-names></name><name><surname>Schatz</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Accurate de novo and transmitted indel detection in exome-capture data using microassembly</article-title><source>Nature Methods</source><volume>11</volume><fpage>1033</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3069</pub-id><pub-id pub-id-type="pmid">25128977</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Staaf</surname> <given-names>J</given-names></name><name><surname>Ramakrishna</surname> <given-names>M</given-names></name><name><surname>Glodzik</surname> <given-names>D</given-names></name><name><surname>Zou</surname> <given-names>X</given-names></name><name><surname>Martincorena</surname> <given-names>I</given-names></name><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Ju</surname> <given-names>YS</given-names></name><name><surname>Smid</surname> <given-names>M</given-names></name><name><surname>Brinkman</surname> <given-names>AB</given-names></name><name><surname>Morganella</surname> <given-names>S</given-names></name><name><surname>Aure</surname> <given-names>MR</given-names></name><name><surname>Lingjærde</surname> <given-names>OC</given-names></name><name><surname>Langerød</surname> <given-names>A</given-names></name><name><surname>Ringnér</surname> <given-names>M</given-names></name><name><surname>Ahn</surname> <given-names>SM</given-names></name><name><surname>Boyault</surname> <given-names>S</given-names></name><name><surname>Brock</surname> <given-names>JE</given-names></name><name><surname>Broeks</surname> <given-names>A</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Desmedt</surname> <given-names>C</given-names></name><name><surname>Dirix</surname> <given-names>L</given-names></name><name><surname>Dronov</surname> <given-names>S</given-names></name><name><surname>Fatima</surname> <given-names>A</given-names></name><name><surname>Foekens</surname> <given-names>JA</given-names></name><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Hooijer</surname> <given-names>GK</given-names></name><name><surname>Jang</surname> <given-names>SJ</given-names></name><name><surname>Jones</surname> <given-names>DR</given-names></name><name><surname>Kim</surname> <given-names>HY</given-names></name><name><surname>King</surname> <given-names>TA</given-names></name><name><surname>Krishnamurthy</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Lee</surname> <given-names>JY</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>Mustonen</surname> <given-names>V</given-names></name><name><surname>O'Meara</surname> <given-names>S</given-names></name><name><surname>Pauporté</surname> <given-names>I</given-names></name><name><surname>Pivot</surname> <given-names>X</given-names></name><name><surname>Purdie</surname> <given-names>CA</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Ramakrishnan</surname> <given-names>K</given-names></name><name><surname>Rodríguez-González</surname> <given-names>FG</given-names></name><name><surname>Romieu</surname> <given-names>G</given-names></name><name><surname>Sieuwerts</surname> <given-names>AM</given-names></name><name><surname>Simpson</surname> <given-names>PT</given-names></name><name><surname>Shepherd</surname> <given-names>R</given-names></name><name><surname>Stebbings</surname> <given-names>L</given-names></name><name><surname>Stefansson</surname> <given-names>OA</given-names></name><name><surname>Teague</surname> <given-names>J</given-names></name><name><surname>Tommasi</surname> <given-names>S</given-names></name><name><surname>Treilleux</surname> <given-names>I</given-names></name><name><surname>Van den Eynden</surname> <given-names>GG</given-names></name><name><surname>Vermeulen</surname> <given-names>P</given-names></name><name><surname>Vincent-Salomon</surname> <given-names>A</given-names></name><name><surname>Yates</surname> <given-names>L</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>van't Veer</surname> <given-names>L</given-names></name><name><surname>Tutt</surname> <given-names>A</given-names></name><name><surname>Knappskog</surname> <given-names>S</given-names></name><name><surname>Tan</surname> <given-names>BK</given-names></name><name><surname>Jonkers</surname> <given-names>J</given-names></name><name><surname>Borg</surname> <given-names>Å</given-names></name><name><surname>Ueno</surname> <given-names>NT</given-names></name><name><surname>Sotiriou</surname> <given-names>C</given-names></name><name><surname>Viari</surname> <given-names>A</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Span</surname> <given-names>PN</given-names></name><name><surname>Van Laere</surname> <given-names>S</given-names></name><name><surname>Lakhani</surname> <given-names>SR</given-names></name><name><surname>Eyfjord</surname> <given-names>JE</given-names></name><name><surname>Thompson</surname> <given-names>AM</given-names></name><name><surname>Birney</surname> <given-names>E</given-names></name><name><surname>Stunnenberg</surname> <given-names>HG</given-names></name><name><surname>van de Vijver</surname> <given-names>MJ</given-names></name><name><surname>Martens</surname> <given-names>JW</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Kong</surname> <given-names>G</given-names></name><name><surname>Thomas</surname> <given-names>G</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Landscape of somatic mutations in 560 breast cancer whole-genome sequences</article-title><source>Nature</source><volume>534</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nature17676</pub-id><pub-id pub-id-type="pmid">27135926</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>HS</given-names></name><name><surname>Kim</surname> <given-names>MS</given-names></name><name><surname>Huh</surname> <given-names>SH</given-names></name><name><surname>Park</surname> <given-names>J</given-names></name><name><surname>Chung</surname> <given-names>J</given-names></name><name><surname>Kang</surname> <given-names>SS</given-names></name><name><surname>Choi</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>2573</fpage><lpage>2578</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110299200</pub-id><pub-id pub-id-type="pmid">11707464</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmigiani</surname> <given-names>G</given-names></name><name><surname>Boca</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Velculescu</surname> <given-names>V</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Design and analysis issues in genome-wide somatic mutation studies of cancer</article-title><source>Genomics</source><volume>93</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2008.07.005</pub-id><pub-id pub-id-type="pmid">18692126</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plaisier</surname> <given-names>SB</given-names></name><name><surname>Taschereau</surname> <given-names>R</given-names></name><name><surname>Wong</surname> <given-names>JA</given-names></name><name><surname>Graeber</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures</article-title><source>Nucleic Acids Research</source><volume>38</volume><elocation-id>e169</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkq636</pub-id><pub-id pub-id-type="pmid">20660011</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradeep</surname> <given-names>CR</given-names></name><name><surname>Köstler</surname> <given-names>WJ</given-names></name><name><surname>Lauriola</surname> <given-names>M</given-names></name><name><surname>Granit</surname> <given-names>RZ</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Jacob-Hirsch</surname> <given-names>J</given-names></name><name><surname>Rechavi</surname> <given-names>G</given-names></name><name><surname>Nair</surname> <given-names>HB</given-names></name><name><surname>Hennessy</surname> <given-names>BT</given-names></name><name><surname>Gonzalez-Angulo</surname> <given-names>AM</given-names></name><name><surname>Tekmal</surname> <given-names>RR</given-names></name><name><surname>Ben-Porath</surname> <given-names>I</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Domany</surname> <given-names>E</given-names></name><name><surname>Yarden</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling</article-title><source>Oncogene</source><volume>31</volume><fpage>907</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.279</pub-id><pub-id pub-id-type="pmid">21743488</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname> <given-names>AR</given-names></name><name><surname>Hall</surname> <given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saldanha</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Java Treeview--extensible visualization of microarray data</article-title><source>Bioinformatics</source><volume>20</volume><fpage>3246</fpage><lpage>3248</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bth349</pub-id><pub-id pub-id-type="pmid">15180930</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Garcia</surname> <given-names>F</given-names></name><name><surname>Villagrasa</surname> <given-names>P</given-names></name><name><surname>Matsui</surname> <given-names>J</given-names></name><name><surname>Kotliar</surname> <given-names>D</given-names></name><name><surname>Castro</surname> <given-names>V</given-names></name><name><surname>Akavia</surname> <given-names>UD</given-names></name><name><surname>Chen</surname> <given-names>BJ</given-names></name><name><surname>Saucedo-Cuevas</surname> <given-names>L</given-names></name><name><surname>Rodriguez Barrueco</surname> <given-names>R</given-names></name><name><surname>Llobet-Navas</surname> <given-names>D</given-names></name><name><surname>Silva</surname> <given-names>JM</given-names></name><name><surname>Pe'er</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Integration of genomic data enables selective discovery of breast cancer drivers</article-title><source>Cell</source><volume>159</volume><fpage>1461</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.10.048</pub-id><pub-id pub-id-type="pmid">25433701</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathirapongsasuti</surname> <given-names>JF</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Horst</surname> <given-names>BA</given-names></name><name><surname>Brunner</surname> <given-names>G</given-names></name><name><surname>Cochran</surname> <given-names>AJ</given-names></name><name><surname>Binder</surname> <given-names>S</given-names></name><name><surname>Quackenbush</surname> <given-names>J</given-names></name><name><surname>Nelson</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV</article-title><source>Bioinformatics</source><volume>27</volume><fpage>2648</fpage><lpage>2654</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr462</pub-id><pub-id pub-id-type="pmid">21828086</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname> <given-names>CT</given-names></name><name><surname>Wong</surname> <given-names>WS</given-names></name><name><surname>Swamy</surname> <given-names>S</given-names></name><name><surname>Becq</surname> <given-names>J</given-names></name><name><surname>Murray</surname> <given-names>LJ</given-names></name><name><surname>Cheetham</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs</article-title><source>Bioinformatics</source><volume>28</volume><fpage>1811</fpage><lpage>1817</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts271</pub-id><pub-id pub-id-type="pmid">22581179</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname> <given-names>J</given-names></name><name><surname>Arganda-Carreras</surname> <given-names>I</given-names></name><name><surname>Frise</surname> <given-names>E</given-names></name><name><surname>Kaynig</surname> <given-names>V</given-names></name><name><surname>Longair</surname> <given-names>M</given-names></name><name><surname>Pietzsch</surname> <given-names>T</given-names></name><name><surname>Preibisch</surname> <given-names>S</given-names></name><name><surname>Rueden</surname> <given-names>C</given-names></name><name><surname>Saalfeld</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>B</given-names></name><name><surname>Tinevez</surname> <given-names>JY</given-names></name><name><surname>White</surname> <given-names>DJ</given-names></name><name><surname>Hartenstein</surname> <given-names>V</given-names></name><name><surname>Eliceiri</surname> <given-names>K</given-names></name><name><surname>Tomancak</surname> <given-names>P</given-names></name><name><surname>Cardona</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname> <given-names>SP</given-names></name><name><surname>Roth</surname> <given-names>A</given-names></name><name><surname>Goya</surname> <given-names>R</given-names></name><name><surname>Oloumi</surname> <given-names>A</given-names></name><name><surname>Ha</surname> <given-names>G</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Turashvili</surname> <given-names>G</given-names></name><name><surname>Ding</surname> <given-names>J</given-names></name><name><surname>Tse</surname> <given-names>K</given-names></name><name><surname>Haffari</surname> <given-names>G</given-names></name><name><surname>Bashashati</surname> <given-names>A</given-names></name><name><surname>Prentice</surname> <given-names>LM</given-names></name><name><surname>Khattra</surname> <given-names>J</given-names></name><name><surname>Burleigh</surname> <given-names>A</given-names></name><name><surname>Yap</surname> <given-names>D</given-names></name><name><surname>Bernard</surname> <given-names>V</given-names></name><name><surname>McPherson</surname> <given-names>A</given-names></name><name><surname>Shumansky</surname> <given-names>K</given-names></name><name><surname>Crisan</surname> <given-names>A</given-names></name><name><surname>Giuliany</surname> <given-names>R</given-names></name><name><surname>Heravi-Moussavi</surname> <given-names>A</given-names></name><name><surname>Rosner</surname> <given-names>J</given-names></name><name><surname>Lai</surname> <given-names>D</given-names></name><name><surname>Birol</surname> <given-names>I</given-names></name><name><surname>Varhol</surname> <given-names>R</given-names></name><name><surname>Tam</surname> <given-names>A</given-names></name><name><surname>Dhalla</surname> <given-names>N</given-names></name><name><surname>Zeng</surname> <given-names>T</given-names></name><name><surname>Ma</surname> <given-names>K</given-names></name><name><surname>Chan</surname> <given-names>SK</given-names></name><name><surname>Griffith</surname> <given-names>M</given-names></name><name><surname>Moradian</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>SW</given-names></name><name><surname>Morin</surname> <given-names>GB</given-names></name><name><surname>Watson</surname> <given-names>P</given-names></name><name><surname>Gelmon</surname> <given-names>K</given-names></name><name><surname>Chia</surname> <given-names>S</given-names></name><name><surname>Chin</surname> <given-names>SF</given-names></name><name><surname>Curtis</surname> <given-names>C</given-names></name><name><surname>Rueda</surname> <given-names>OM</given-names></name><name><surname>Pharoah</surname> <given-names>PD</given-names></name><name><surname>Damaraju</surname> <given-names>S</given-names></name><name><surname>Mackey</surname> <given-names>J</given-names></name><name><surname>Hoon</surname> <given-names>K</given-names></name><name><surname>Harkins</surname> <given-names>T</given-names></name><name><surname>Tadigotla</surname> <given-names>V</given-names></name><name><surname>Sigaroudinia</surname> <given-names>M</given-names></name><name><surname>Gascard</surname> <given-names>P</given-names></name><name><surname>Tlsty</surname> <given-names>T</given-names></name><name><surname>Costello</surname> <given-names>JF</given-names></name><name><surname>Meyer</surname> <given-names>IM</given-names></name><name><surname>Eaves</surname> <given-names>CJ</given-names></name><name><surname>Wasserman</surname> <given-names>WW</given-names></name><name><surname>Jones</surname> <given-names>S</given-names></name><name><surname>Huntsman</surname> <given-names>D</given-names></name><name><surname>Hirst</surname> <given-names>M</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Aparicio</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The clonal and mutational evolution spectrum of primary triple-negative breast cancers</article-title><source>Nature</source><volume>486</volume><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1038/nature10933</pub-id><pub-id pub-id-type="pmid">22495314</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname> <given-names>RL</given-names></name><name><surname>Miller</surname> <given-names>KD</given-names></name><name><surname>Jemal</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer statistics, 2015</article-title><source>CA: A Cancer Journal for Clinicians</source><volume>65</volume><fpage>5</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3322/caac.21254</pub-id><pub-id pub-id-type="pmid">25559415</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smedley</surname> <given-names>D</given-names></name><name><surname>Haider</surname> <given-names>S</given-names></name><name><surname>Durinck</surname> <given-names>S</given-names></name><name><surname>Pandini</surname> <given-names>L</given-names></name><name><surname>Provero</surname> <given-names>P</given-names></name><name><surname>Allen</surname> <given-names>J</given-names></name><name><surname>Arnaiz</surname> <given-names>O</given-names></name><name><surname>Awedh</surname> <given-names>MH</given-names></name><name><surname>Baldock</surname> <given-names>R</given-names></name><name><surname>Barbiera</surname> <given-names>G</given-names></name><name><surname>Bardou</surname> <given-names>P</given-names></name><name><surname>Beck</surname> <given-names>T</given-names></name><name><surname>Blake</surname> <given-names>A</given-names></name><name><surname>Bonierbale</surname> <given-names>M</given-names></name><name><surname>Brookes</surname> <given-names>AJ</given-names></name><name><surname>Bucci</surname> <given-names>G</given-names></name><name><surname>Buetti</surname> <given-names>I</given-names></name><name><surname>Burge</surname> <given-names>S</given-names></name><name><surname>Cabau</surname> <given-names>C</given-names></name><name><surname>Carlson</surname> <given-names>JW</given-names></name><name><surname>Chelala</surname> <given-names>C</given-names></name><name><surname>Chrysostomou</surname> <given-names>C</given-names></name><name><surname>Cittaro</surname> <given-names>D</given-names></name><name><surname>Collin</surname> <given-names>O</given-names></name><name><surname>Cordova</surname> <given-names>R</given-names></name><name><surname>Cutts</surname> <given-names>RJ</given-names></name><name><surname>Dassi</surname> <given-names>E</given-names></name><name><surname>Di Genova</surname> <given-names>A</given-names></name><name><surname>Djari</surname> <given-names>A</given-names></name><name><surname>Esposito</surname> <given-names>A</given-names></name><name><surname>Estrella</surname> <given-names>H</given-names></name><name><surname>Eyras</surname> <given-names>E</given-names></name><name><surname>Fernandez-Banet</surname> <given-names>J</given-names></name><name><surname>Forbes</surname> <given-names>S</given-names></name><name><surname>Free</surname> <given-names>RC</given-names></name><name><surname>Fujisawa</surname> <given-names>T</given-names></name><name><surname>Gadaleta</surname> <given-names>E</given-names></name><name><surname>Garcia-Manteiga</surname> <given-names>JM</given-names></name><name><surname>Goodstein</surname> <given-names>D</given-names></name><name><surname>Gray</surname> <given-names>K</given-names></name><name><surname>Guerra-Assunção</surname> <given-names>JA</given-names></name><name><surname>Haggarty</surname> <given-names>B</given-names></name><name><surname>Han</surname> <given-names>DJ</given-names></name><name><surname>Han</surname> <given-names>BW</given-names></name><name><surname>Harris</surname> <given-names>T</given-names></name><name><surname>Harshbarger</surname> <given-names>J</given-names></name><name><surname>Hastings</surname> <given-names>RK</given-names></name><name><surname>Hayes</surname> <given-names>RD</given-names></name><name><surname>Hoede</surname> <given-names>C</given-names></name><name><surname>Hu</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>ZL</given-names></name><name><surname>Hutchins</surname> <given-names>L</given-names></name><name><surname>Kan</surname> <given-names>Z</given-names></name><name><surname>Kawaji</surname> <given-names>H</given-names></name><name><surname>Keliet</surname> <given-names>A</given-names></name><name><surname>Kerhornou</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Kinsella</surname> <given-names>R</given-names></name><name><surname>Klopp</surname> <given-names>C</given-names></name><name><surname>Kong</surname> <given-names>L</given-names></name><name><surname>Lawson</surname> <given-names>D</given-names></name><name><surname>Lazarevic</surname> <given-names>D</given-names></name><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Letellier</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>CY</given-names></name><name><surname>Lio</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>CJ</given-names></name><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>Maass</surname> <given-names>A</given-names></name><name><surname>Mariette</surname> <given-names>J</given-names></name><name><surname>Maurel</surname> <given-names>T</given-names></name><name><surname>Merella</surname> <given-names>S</given-names></name><name><surname>Mohamed</surname> <given-names>AM</given-names></name><name><surname>Moreews</surname> <given-names>F</given-names></name><name><surname>Nabihoudine</surname> <given-names>I</given-names></name><name><surname>Ndegwa</surname> <given-names>N</given-names></name><name><surname>Noirot</surname> <given-names>C</given-names></name><name><surname>Perez-Llamas</surname> <given-names>C</given-names></name><name><surname>Primig</surname> <given-names>M</given-names></name><name><surname>Quattrone</surname> <given-names>A</given-names></name><name><surname>Quesneville</surname> <given-names>H</given-names></name><name><surname>Rambaldi</surname> <given-names>D</given-names></name><name><surname>Reecy</surname> <given-names>J</given-names></name><name><surname>Riba</surname> <given-names>M</given-names></name><name><surname>Rosanoff</surname> <given-names>S</given-names></name><name><surname>Saddiq</surname> <given-names>AA</given-names></name><name><surname>Salas</surname> <given-names>E</given-names></name><name><surname>Sallou</surname> <given-names>O</given-names></name><name><surname>Shepherd</surname> <given-names>R</given-names></name><name><surname>Simon</surname> <given-names>R</given-names></name><name><surname>Sperling</surname> <given-names>L</given-names></name><name><surname>Spooner</surname> <given-names>W</given-names></name><name><surname>Staines</surname> <given-names>DM</given-names></name><name><surname>Steinbach</surname> <given-names>D</given-names></name><name><surname>Stone</surname> <given-names>K</given-names></name><name><surname>Stupka</surname> <given-names>E</given-names></name><name><surname>Teague</surname> <given-names>JW</given-names></name><name><surname>Dayem Ullah</surname> <given-names>AZ</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Ware</surname> <given-names>D</given-names></name><name><surname>Wong-Erasmus</surname> <given-names>M</given-names></name><name><surname>Youens-Clark</surname> <given-names>K</given-names></name><name><surname>Zadissa</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>SJ</given-names></name><name><surname>Kasprzyk</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The BioMart community portal: an innovative alternative to large, centralized data repositories</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>W589</fpage><lpage>W598</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv350</pub-id><pub-id pub-id-type="pmid">25897122</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname> <given-names>PJ</given-names></name><name><surname>Tarpey</surname> <given-names>PS</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Greenman</surname> <given-names>C</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Varela</surname> <given-names>I</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Yates</surname> <given-names>LR</given-names></name><name><surname>Papaemmanuil</surname> <given-names>E</given-names></name><name><surname>Beare</surname> <given-names>D</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Cheverton</surname> <given-names>A</given-names></name><name><surname>Gamble</surname> <given-names>J</given-names></name><name><surname>Hinton</surname> <given-names>J</given-names></name><name><surname>Jia</surname> <given-names>M</given-names></name><name><surname>Jayakumar</surname> <given-names>A</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Latimer</surname> <given-names>C</given-names></name><name><surname>Lau</surname> <given-names>KW</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>McBride</surname> <given-names>DJ</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>Mudie</surname> <given-names>L</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Rad</surname> <given-names>R</given-names></name><name><surname>Chapman</surname> <given-names>MS</given-names></name><name><surname>Teague</surname> <given-names>J</given-names></name><name><surname>Easton</surname> <given-names>D</given-names></name><name><surname>Langerød</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>MT</given-names></name><name><surname>Shen</surname> <given-names>CY</given-names></name><name><surname>Tee</surname> <given-names>BT</given-names></name><name><surname>Huimin</surname> <given-names>BW</given-names></name><name><surname>Broeks</surname> <given-names>A</given-names></name><name><surname>Vargas</surname> <given-names>AC</given-names></name><name><surname>Turashvili</surname> <given-names>G</given-names></name><name><surname>Martens</surname> <given-names>J</given-names></name><name><surname>Fatima</surname> <given-names>A</given-names></name><name><surname>Miron</surname> <given-names>P</given-names></name><name><surname>Chin</surname> <given-names>SF</given-names></name><name><surname>Thomas</surname> <given-names>G</given-names></name><name><surname>Boyault</surname> <given-names>S</given-names></name><name><surname>Mariani</surname> <given-names>O</given-names></name><name><surname>Lakhani</surname> <given-names>SR</given-names></name><name><surname>van de Vijver</surname> <given-names>M</given-names></name><name><surname>van 't Veer</surname> <given-names>L</given-names></name><name><surname>Foekens</surname> <given-names>J</given-names></name><name><surname>Desmedt</surname> <given-names>C</given-names></name><name><surname>Sotiriou</surname> <given-names>C</given-names></name><name><surname>Tutt</surname> <given-names>A</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Reis-Filho</surname> <given-names>JS</given-names></name><name><surname>Aparicio</surname> <given-names>SA</given-names></name><name><surname>Salomon</surname> <given-names>AV</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><collab>Oslo Breast Cancer Consortium (OSBREAC)</collab></person-group><year iso-8601-date="2012">2012</year><article-title>The landscape of cancer genes and mutational processes in breast cancer</article-title><source>Nature</source><volume>486</volume><fpage>400</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/nature11017</pub-id><pub-id pub-id-type="pmid">22722201</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taraseviciute</surname> <given-names>A</given-names></name><name><surname>Vincent</surname> <given-names>BT</given-names></name><name><surname>Schedin</surname> <given-names>P</given-names></name><name><surname>Jones</surname> <given-names>PL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function</article-title><source>The American Journal of Pathology</source><volume>176</volume><fpage>827</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090006</pub-id><pub-id pub-id-type="pmid">20042668</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorvaldsdóttir</surname> <given-names>H</given-names></name><name><surname>Robinson</surname> <given-names>JT</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration</article-title><source>Briefings in Bioinformatics</source><volume>14</volume><fpage>178</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1093/bib/bbs017</pub-id><pub-id pub-id-type="pmid">22517427</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tournier</surname> <given-names>C</given-names></name><name><surname>Dong</surname> <given-names>C</given-names></name><name><surname>Turner</surname> <given-names>TK</given-names></name><name><surname>Jones</surname> <given-names>SN</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines</article-title><source>Genes &amp; Development</source><volume>15</volume><fpage>1419</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1101/gad.888501</pub-id><pub-id pub-id-type="pmid">11390361</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tournier</surname> <given-names>C</given-names></name><name><surname>Hess</surname> <given-names>P</given-names></name><name><surname>Yang</surname> <given-names>DD</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Turner</surname> <given-names>TK</given-names></name><name><surname>Nimnual</surname> <given-names>A</given-names></name><name><surname>Bar-Sagi</surname> <given-names>D</given-names></name><name><surname>Jones</surname> <given-names>SN</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway</article-title><source>Science</source><volume>288</volume><fpage>870</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1126/science.288.5467.870</pub-id><pub-id pub-id-type="pmid">10797012</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Roberts</surname> <given-names>A</given-names></name><name><surname>Goff</surname> <given-names>L</given-names></name><name><surname>Pertea</surname> <given-names>G</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Kelley</surname> <given-names>DR</given-names></name><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name><name><surname>Rinn</surname> <given-names>JL</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and cufflinks</article-title><source>Nature Protocols</source><volume>7</volume><fpage>562</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.016</pub-id><pub-id pub-id-type="pmid">22383036</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Williams</surname> <given-names>BA</given-names></name><name><surname>Pertea</surname> <given-names>G</given-names></name><name><surname>Mortazavi</surname> <given-names>A</given-names></name><name><surname>Kwan</surname> <given-names>G</given-names></name><name><surname>van Baren</surname> <given-names>MJ</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name><name><surname>Wold</surname> <given-names>BJ</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1038/nbt.1621</pub-id><pub-id pub-id-type="pmid">20436464</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Meter</surname> <given-names>M</given-names></name><name><surname>Simon</surname> <given-names>M</given-names></name><name><surname>Tombline</surname> <given-names>G</given-names></name><name><surname>May</surname> <given-names>A</given-names></name><name><surname>Morello</surname> <given-names>TD</given-names></name><name><surname>Hubbard</surname> <given-names>BP</given-names></name><name><surname>Bredbenner</surname> <given-names>K</given-names></name><name><surname>Park</surname> <given-names>R</given-names></name><name><surname>Sinclair</surname> <given-names>DA</given-names></name><name><surname>Bohr</surname> <given-names>VA</given-names></name><name><surname>Gorbunova</surname> <given-names>V</given-names></name><name><surname>Seluanov</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>JNK phosphorylates SIRT6 to stimulate DNA Double-Strand break repair in response to oxidative stress by recruiting PARP1 to DNA breaks</article-title><source>Cell Reports</source><volume>16</volume><fpage>2641</fpage><lpage>2650</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.006</pub-id><pub-id pub-id-type="pmid">27568560</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname> <given-names>JJ</given-names></name><name><surname>Kennedy</surname> <given-names>NJ</given-names></name><name><surname>Lamb</surname> <given-names>JA</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>2871</fpage><lpage>2882</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.8.2871-2882.2003</pub-id><pub-id pub-id-type="pmid">12665585</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vousden</surname> <given-names>KH</given-names></name><name><surname>Prives</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Blinded by the light: the growing complexity of p53</article-title><source>Cell</source><volume>137</volume><fpage>413</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.037</pub-id><pub-id pub-id-type="pmid">19410540</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname> <given-names>KU</given-names></name><name><surname>Wall</surname> <given-names>RJ</given-names></name><name><surname>St-Onge</surname> <given-names>L</given-names></name><name><surname>Gruss</surname> <given-names>P</given-names></name><name><surname>Wynshaw-Boris</surname> <given-names>A</given-names></name><name><surname>Garrett</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Furth</surname> <given-names>PA</given-names></name><name><surname>Hennighausen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Cre-mediated gene deletion in the mammary gland</article-title><source>Nucleic Acids Research</source><volume>25</volume><fpage>4323</fpage><lpage>4330</lpage><pub-id pub-id-type="doi">10.1093/nar/25.21.4323</pub-id><pub-id pub-id-type="pmid">9336464</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Duncan</surname> <given-names>D</given-names></name><name><surname>Shi</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>WEB-based GEne SeT AnaLysis toolkit (WebGestalt): update 2013</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>W77</fpage><lpage>W83</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt439</pub-id><pub-id pub-id-type="pmid">23703215</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Waters</surname> <given-names>J</given-names></name><name><surname>Leung</surname> <given-names>ML</given-names></name><name><surname>Unruh</surname> <given-names>A</given-names></name><name><surname>Roh</surname> <given-names>W</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Scheet</surname> <given-names>P</given-names></name><name><surname>Vattathil</surname> <given-names>S</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><name><surname>Multani</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Zhao</surname> <given-names>R</given-names></name><name><surname>Michor</surname> <given-names>F</given-names></name><name><surname>Meric-Bernstam</surname> <given-names>F</given-names></name><name><surname>Navin</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal evolution in breast cancer revealed by single nucleus genome sequencing</article-title><source>Nature</source><volume>512</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/nature13600</pub-id><pub-id pub-id-type="pmid">25079324</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname> <given-names>HC</given-names></name><name><surname>Avivar-Valderas</surname> <given-names>A</given-names></name><name><surname>Sosa</surname> <given-names>MS</given-names></name><name><surname>Girnius</surname> <given-names>N</given-names></name><name><surname>Farias</surname> <given-names>EF</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name><name><surname>Aguirre-Ghiso</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>p38α signaling induces anoikis and lumen formation during mammary morphogenesis</article-title><source>Science Signaling</source><volume>4</volume><elocation-id>ra34</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2001684</pub-id><pub-id pub-id-type="pmid">21610252</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>Wallis</surname> <given-names>JW</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>PathScan: a tool for discerning mutational significance in groups of putative cancer genes</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1595</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr193</pub-id><pub-id pub-id-type="pmid">21498403</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitmarsh</surname> <given-names>AJ</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Role of mitogen-activated protein kinase kinase 4 in cancer</article-title><source>Oncogene</source><volume>26</volume><fpage>3172</fpage><lpage>3184</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210410</pub-id><pub-id pub-id-type="pmid">17496914</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilm</surname> <given-names>A</given-names></name><name><surname>Aw</surname> <given-names>PP</given-names></name><name><surname>Bertrand</surname> <given-names>D</given-names></name><name><surname>Yeo</surname> <given-names>GH</given-names></name><name><surname>Ong</surname> <given-names>SH</given-names></name><name><surname>Wong</surname> <given-names>CH</given-names></name><name><surname>Khor</surname> <given-names>CC</given-names></name><name><surname>Petric</surname> <given-names>R</given-names></name><name><surname>Hibberd</surname> <given-names>ML</given-names></name><name><surname>Nagarajan</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>11189</fpage><lpage>11201</lpage><pub-id pub-id-type="doi">10.1093/nar/gks918</pub-id><pub-id pub-id-type="pmid">23066108</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>X</given-names></name><name><surname>Kaoud</surname> <given-names>TS</given-names></name><name><surname>Edupuganti</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Kogawa</surname> <given-names>T</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Chauhan</surname> <given-names>GB</given-names></name><name><surname>Giannoukos</surname> <given-names>DN</given-names></name><name><surname>Qi</surname> <given-names>Y</given-names></name><name><surname>Tripathy</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Dalby</surname> <given-names>KN</given-names></name><name><surname>Bartholomeusz</surname> <given-names>C</given-names></name><name><surname>Ueno</surname> <given-names>NT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun</article-title><source>Oncogene</source><volume>36</volume><fpage>2599</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.417</pub-id><pub-id pub-id-type="pmid">27941886</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>K</given-names></name><name><surname>Schulz</surname> <given-names>MH</given-names></name><name><surname>Long</surname> <given-names>Q</given-names></name><name><surname>Apweiler</surname> <given-names>R</given-names></name><name><surname>Ning</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2865</fpage><lpage>2871</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp394</pub-id><pub-id pub-id-type="pmid">19561018</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youn</surname> <given-names>A</given-names></name><name><surname>Simon</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Identifying cancer driver genes in tumor genome sequencing studies</article-title><source>Bioinformatics</source><volume>27</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq630</pub-id><pub-id pub-id-type="pmid">21169372</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>TL</given-names></name><name><surname>Cantley</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>PI3K pathway alterations in cancer: variations on a theme</article-title><source>Oncogene</source><volume>27</volume><fpage>5497</fpage><lpage>5510</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.245</pub-id><pub-id pub-id-type="pmid">18794884</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yujiri</surname> <given-names>T</given-names></name><name><surname>Ware</surname> <given-names>M</given-names></name><name><surname>Widmann</surname> <given-names>C</given-names></name><name><surname>Oyer</surname> <given-names>R</given-names></name><name><surname>Russell</surname> <given-names>D</given-names></name><name><surname>Chan</surname> <given-names>E</given-names></name><name><surname>Zaitsu</surname> <given-names>Y</given-names></name><name><surname>Clarke</surname> <given-names>P</given-names></name><name><surname>Tyler</surname> <given-names>K</given-names></name><name><surname>Oka</surname> <given-names>Y</given-names></name><name><surname>Fanger</surname> <given-names>GR</given-names></name><name><surname>Henson</surname> <given-names>P</given-names></name><name><surname>Johnson</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation</article-title><source>PNAS</source><volume>97</volume><fpage>7272</fpage><lpage>7277</lpage><pub-id pub-id-type="doi">10.1073/pnas.130176697</pub-id><pub-id pub-id-type="pmid">10852963</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname> <given-names>L</given-names></name><name><surname>Rosenberg</surname> <given-names>A</given-names></name><name><surname>Bergami</surname> <given-names>KC</given-names></name><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Xuan</surname> <given-names>Z</given-names></name><name><surname>Jaffe</surname> <given-names>AB</given-names></name><name><surname>Allred</surname> <given-names>C</given-names></name><name><surname>Muthuswamy</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma</article-title><source>Cell</source><volume>135</volume><fpage>865</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.09.045</pub-id><pub-id pub-id-type="pmid">19041750</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.36389.043</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Frame</surname><given-names>Margaret C</given-names></name><role>Reviewing Editor</role><aff id="aff5"><institution>University of Edinburgh</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;The cJUN NH<sub>2</sub>-terminal kinase (<italic>JNK</italic>) signaling pathway promotes genome stability and prevents tumor initiation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jonathan Cooper as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Your paper has been seen by three reviewers, and myself, and we are very happy to consider publication after some revisions that potentially include some new data, some points of clarification/further discussion, and some addressing of minor points. Overall, all three reviewers consider the work presented to be novel and interesting, adding significantly to the existing literature on the role of <italic>JNK</italic> in tumorigenesis, and the context dependency of that. There are some suggested additional data that would enhance mechanistic advance if these can be added, and quite a few points of clarification or discussion that the reviewers felt would be important and/or add to the paper. Some of these were considered important to avoid slightly superficial interpretation of some data in places, particularly around what the model used here was actually reporting. These points are outlined below. We look forward to seeing a revised version.</p><p><italic>Major points:</italic> </p><p>1) The authors cannot use the wording that <italic>JNK</italic> deletion is 'sufficient' to cause tumors? Only 10 of 32 ME-ko mice had tumors. For Figure 1C the authors need to be explicit in the ages of the mice under observation. What is the latency period of the tumors and MIN lesions? How long were control animals followed? It is surprising the authors have chosen JNKf/f (Cre-negative) animals as their control. Was any <italic>WAP-Cre;JNK</italic>-wt cohort aged during the study?</p><p>2) The main conclusion is that <italic>JNK</italic> suppresses breast cancer initiation; however the authors have recently published that <italic>JNK</italic> deletion results in a delay in mammary gland involution (Girnius et al., CDD). Therefore, could the lesions observed in Figure 7 be due to a lack of clearance post-weaning? This could lead to an expanded pool of cells susceptible to transformation and so a quirk of the <italic>WAP-Cre</italic> model. Have the authors considered using an alternative mammary-specific Cre driver such as <italic>K8-Cre</italic> or <italic>MMTV-Cre</italic> which would obviate the need to induce lactation? At the very least, this should be discussed in more detail. Can <italic>JNK</italic> be deleted in established tumors, either using an inhibitor or perhaps by way of an inducible knockdown orthotopic model?</p><p>3) There are 3 examples of ME-KO tumours in Figure 1D but the authors need to say if these are adenocarcinoma or adenosquamous carcinoma. Ideally at least two examples of each tumor type should be shown. It is not clear if the adenosquamous carcinomas originate in a <italic>JNK</italic>-deleted cell type since the <italic>WAP-cre</italic> driver is CK8-specific (Figure 1A) yet the adenosquamous lesions are predominately CK5 positive. Furthermore, there is no evidence for the trans-differentiation unless the authors can show these CK5+ tumours are <italic>JNK</italic>-deleted.</p><p>4) The RNAseq data presented in Figure 2 demonstrates an upregulation of WNT target genes in ME<sup>KO</sup> cells, leading the authors to suggest that ME<sup>KO</sup> tumors could exploit WNT signalling to drive proliferation. Validating this observation at the protein level through IHC of tumor tissue or Western blotting of ME<sup>WT</sup> and ME<sup>KO</sup> cell lines would add confidence to this proposed mechanism. Are WNT pathway components differentially expressed between <italic>JNK</italic><sup>WT</sup> and <italic>JNK</italic><sup>KO</sup> tumor cells in the p53mut background? Based on data in Figure 2E and 2F, would authors predict that <italic>JNK</italic><sup>KO</sup> tumor cells should be more sensitive to WNT pathway inhibitors? Has this been tested?</p><p>5) The detection of genomic instability indicators in ME<sup>KO</sup> tumor cell lines is interesting but perhaps expected when comparing tumor cells with normal epithelial cells. It would have been useful to compare ME<sup>KO</sup> with ME<sup>WT</sup> tumor cell lines. It does looks like in the p53mut background, <italic>JNK</italic><sup>KO</sup> cells have less SNVs and indels than <italic>JNK</italic><sup>WT</sup> cells (Figure 1—figure supplement 2A). Authors should comment on this.</p><p>6) Do gene expression changes associated with <italic>JNK</italic> deficiency in mammary tumor cells correlate with previously published gene signatures associated with genomic instability or DNA damage?</p><p><italic>Points for clarification/discussion:</italic> </p><p>7) Human breast cancers retain expression of JNK1 and JNK2 but exhibit inactivating mutations in upstream components, which will strongly impair activation of <italic>JNK</italic>. This is obviously not the same as the complete ablation of <italic>JNK</italic> expression that the authors employ in this model. Whilst the data presented are strong and provide important new insights into the role of <italic>JNK</italic> in this murine model, the authors do need to explicitly acknowledge and comment on this limitation of their model.</p><p>8) At several places in the manuscript (Introduction and Conclusion) the authors state that their discovery that loss of JNK1/2 expression promotes breast cancer may 'present an opportunity for therapeutic intervention'. It is not immediately obvious how a small molecule could rescue the effects of losing JNK1/2 expression to prevent genome instability. Presumably they are thinking about a disease stratification approach in which those breast cancers with loss of function mutations on the <italic>JNK</italic> pathway and enhanced genome stability may be more susceptible to intervention with drugs targeting DNA Damage Response (DDR) pathways, analogous to synthetic lethality that has helped to drive approval of PARPi? Or do they envisage combination of JNKi and DDRi as being synthetic lethal in cells that do not have <italic>JNK</italic> pathway mutations? A little more information here, or discussion, would help to clarify ideas and potential significance for the reader.</p><p>9) In Figure 3 and Figure 3—figure supplement 2 the authors describe how the <italic><underline>Kras</underline></italic> locus is more frequently amplified in JNK<sup>WT</sup> mice compared to JNK<sup>KO</sup>. Could the authors comment on the significance of this observation? Are they proposing that because the JNK<sup>KO</sup> tumours display increased genome instability they are likely to acquire many more oncogenic events and thus become less reliant on the amplification of the <italic>Kras</italic> locus which is prevalent in the JNK<sup>WT</sup> mice?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.36389.044</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>Major points:</p><disp-quote content-type="editor-comment"><p>1) The authors cannot use the wording that JNK deletion is 'sufficient' to cause tumors? Only 10 of 32 ME-ko mice had tumors. For Figure 1C the authors need to be explicit in the ages of the mice under observation. What is the latency period of the tumors and MIN lesions? How long were control animals followed? It is surprising the authors have chosen JNKf/f (Cre-negative) animals as their control. Was any WAP-Cre;JNK-wt cohort aged during the study?</p></disp-quote><p>a) We agree – we were wrong to state that <italic>JNK</italic>-deficiency is sufficient for tumor formation since tumors were not found in all <italic>JNK</italic>-deficient mice. We have corrected the text to fix this error.</p><p>b) The source data file for Figure 1C provides detailed information concerning the tumors and MIN lesions, including the age of the mice.</p><p>c) We examined tumors in Cre<sup>+</sup> Control mice (<italic>Cre<sup>+</sup> Jnk1<sup>+/+</sup> Jnk2<sup>+/+</sup></italic>) and Flox Control mice (<italic>Cre<sup>-</sup> Jnk1<sup>LoxP/LoxP</sup> Jnk1<sup>LoxP/LoxP</sup></italic>) as well as experimental <italic>JNK</italic>-deficient mice (<italic>Cre<sup>+</sup> Jnk1<sup>LoxP/LoxP</sup> Jnk1<sup>LoxP/LoxP</sup></italic>). All of these data are presented in the source data file. The Flox Control (<italic>Cre<sup>-</sup> Jnk1<sup>LoxP/LoxP</sup> Jnk1<sup>LoxP/LoxP</sup></italic>) and experimental <italic>JNK</italic>-deficient mice (<italic>Cre<sup>+</sup> Jnk1<sup>LoxP/LoxP</sup> Jnk1<sup>LoxP/LoxP</sup></italic>) are litter-mates, while the Cre<sup>+</sup> Control mice were obtained from separate litters. For this reason, we present data using littermate control mice (<italic>Cre<sup>-</sup> Jnk1<sup>LoxP/LoxP</sup> Jnk1<sup>LoxP/LoxP</sup></italic>) and experimental JNKdeficient mice (<italic>Cre<sup>+</sup> Jnk1<sup>LoxP/LoxP</sup> Jnk1<sup>LoxP/LoxP</sup></italic>) in the Figure. Nevertheless, data from both Control strains and the experimental strain are presented in the source data file. No breast tumors were detected in the 22 Cre<sup>+</sup> Control mice (<italic>Cre<sup>+</sup> Jnk1<sup>+/+</sup> Jnk2<sup>+/+</sup></italic>) that were examined.</p><disp-quote content-type="editor-comment"><p>2) The main conclusion is that JNK suppresses breast cancer initiation; however the authors have recently published that JNK deletion results in a delay in mammary gland involution (Girnius et al., CDD). Therefore, could the lesions observed in Figure 7 be due to a lack of clearance post-weaning? This could lead to an expanded pool of cells susceptible to transformation and so a quirk of the WAP-Cre model. Have the authors considered using an alternative mammary-specific Cre driver such as K8-Cre or MMTV-Cre which would obviate the need to induce lactation? At the very least, this should be discussed in more detail. Can JNK be deleted in established tumors, either using an inhibitor or perhaps by way of an inducible knockdown orthotopic model?</p></disp-quote><p>We have revised the paper to cite our paper on the role of <italic>JNK</italic> in involution. We demonstrated that <italic>JNK</italic>-deficiency causes a delay in involution. However, at 14 days post-weaning, we found no differences in breast morphology between control and <italic>JNK</italic>-deficient mice. It is therefore not clear that suppressed involution contributes to the tumor phenotype of <italic>JNK</italic>-deficient mice. However, we have revised the Discussion to discuss this possibility. We did consider the use of <italic>K8-Cre</italic> and <italic>MMTV-Cre</italic> for these studies. However, the expression of <italic>Cre</italic> in these mouse lines is not restricted to the mammary epithelium. The use of these mice is therefore compromised by the ablation of <italic>Jnk</italic> genes in non-mammary tissues. The <italic>WAP-Cre</italic> model causes gene ablation that is restricted to the mammary epithelium.</p><disp-quote content-type="editor-comment"><p>3) There are 3 examples of ME-KO tumours in Figure 1D but the authors need to say if these are adenocarcinoma or adenosquamous carcinoma. Ideally at least two examples of each tumor type should be shown. It is not clear if the adenosquamous carcinomas originate in a JNK-deleted cell type since the WAP-cre driver is CK8-specific (Figure 1A) yet the adenosquamous lesions are predominately CK5 positive. Furthermore, there is no evidence for the trans-differentiation unless the authors can show these CK5+ tumours are JNK-deleted.</p></disp-quote><p>The three ME<sup>KO</sup> tumors in Figure 1D are representative and include one adenocarcinoma, one adenosquamous carcinoma, and one mixed tumor with characteristics of both adenocarcinoma and adenosquamous carcinoma. We have revised the figure legend to make this clear. No <italic>JNK</italic> was detected by immunoblot analysis in the tumor cells isolated from the <italic>JNK</italic>-deficient mice.</p><p>We note that immunoblot analysis demonstrated no <italic>JNK</italic> expression in the adenosquamous carcinoma of <italic>WAPCre<sup>+</sup> Jnk1<sup>LoxP/LoxP</sup> Jnk1<sup>LoxP/LoxP</sup></italic> mice (Figure 1D). This observation suggests that CK5+ adenosquamous carcinoma cells may arise by trans-differentiation of CK8 cells that express Cre, although we acknowledge that this conclusion is speculative. We acknowledge the speculative nature of this conclusion in the subsection “Disruption of JNK signaling causes breast cancer development”.</p><disp-quote content-type="editor-comment"><p>4) The RNAseq data presented in Figure 2 demonstrates an upregulation of WNT target genes in ME<sup>KO</sup> cells, leading the authors to suggest that ME<sup>KO</sup> tumors could exploit WNT signalling to drive proliferation. Validating this observation at the protein level through IHC of tumor tissue or Western blotting of ME<sup>WT</sup> and ME<sup>KO</sup> cell lines would add confidence to this proposed mechanism. Are WNT pathway components differentially expressed between JNK<sup>WT</sup> and JNK<sup>KO</sup> tumor cells in the p53mut background? Based on data in Figure 2E and 2F, would authors predict that JNK<sup>KO</sup> tumor cells should be more sensitive to WNT pathway inhibitors? Has this been tested?</p></disp-quote><p>Our conclusions concerning the role of WNT signaling are based on the data presented in Figure 2 showing increased expression of <italic>Wnt7b</italic> and <italic>Wnt10a</italic> and increased expression of the WNT target genes <italic>Axin2, Myc</italic> and <italic>Ccnd1</italic>. This conclusion is based on gene expression analysis.</p><p>The reviewer requests that we provide protein-based evidence for WNT signaling in the tumor cells. A major signaling axis that mediates WNT function is the stabilization and nuclear accumulation of β-catenin that serves to increase WMT target gene expression. We therefore examined the nuclear accumulation of β-catenin by immunofluorescence analysis. Figure A shows accumulation of β-catenin in the nucleus of JNK-deficient tumor cells. This observation is fully consistent with our data showing that tumor cells from <italic>JNK</italic> knockout mice exhibit increased expression of WNT target genes.</p><p>We tested the role of autocrine Wnt signaling in the cultured tumour cells by examining the effect of the addition of the WNT antagonist DICKKOPF (R&amp;D Systems) to the culture medium. We found that DICKKOPF caused no change in tumor cell proliferation. We omitted these data from the study for two reasons. First, it is not clear that the rate of proliferation is the most important in vitro property of tumour cells. Second, it is not clear that WNT inhibition by DICKKOPFin vitro mimics the effect of WNT signaling inhibition during tumor development in vivo. We believe that substantially more work is required to establish the role of WNT signaling in the observed tumor development and that this is beyond the scope of the current study.</p><fig id="respfig1"><object-id pub-id-type="doi">10.7554/eLife.36389.034</object-id><label>Author response image 1.</label><caption><title>Mammospheres prepared from Control (left panel) and <italic>JNK</italic>-deficient (right panel) tumor cells were embedded in paraffin, sectioned, and stained with DAPI and an antibody to β-catenin.</title><p>We found that β-catenin was restricted to the cytoplasm of Control tumor cells, but β-catenin was detected in both the nucleus and cytoplasm of <italic>JNK</italic>-deficient tumor cells.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-36389-resp-fig1-v1"/></fig><disp-quote content-type="editor-comment"><p>5) The detection of genomic instability indicators in ME<sup>KO</sup> tumor cell lines is interesting but perhaps expected when comparing tumor cells with normal epithelial cells. It would have been useful to compare ME<sup>KO</sup> with ME<sup>WT</sup> tumor cell lines. It does looks like in the p53mut background, JNK<sup>KO</sup> cells have less SNVs and indels than JNK<sup>WT</sup> cells (Figure 1—figure supplement 2A). Authors should comment on this.</p></disp-quote><p>While the number of SNV and indels caused by TRP53 deficiency was greater than that caused by <italic>JNK</italic> deficiency, the number of CNV were similar on both genetic backgrounds. These observations indicate that while both TRP53deficiency and <italic>JNK</italic>-deficiency cause genomic instability, the mechanisms of genomic instability caused by these two pathways is different. We have added additional discussion of this point to the text.</p><disp-quote content-type="editor-comment"><p>6) Do gene expression changes associated with JNK deficiency in mammary tumor cells correlate with previously published gene signatures associated with genomic instability or DNA damage?</p></disp-quote><p>Gene set enrichment analysis demonstrates decreased expression of a “DNA Repair” gene signature by <italic>JNK</italic> deficient tumor cells (Figure 2—figure supplement 1). These data are included in the revised manuscript.</p><p>Points for clarification/discussion:</p><disp-quote content-type="editor-comment"><p>7) Human breast cancers retain expression of JNK1 and JNK2 but exhibit inactivating mutations in upstream components, which will strongly impair activation of JNK. This is obviously not the same as the complete ablation of JNK expression that the authors employ in this model. Whilst the data presented are strong and provide important new insights into the role of JNK in this murine model, the authors do need to explicitly acknowledge and comment on this limitation of their model.</p></disp-quote><p>We agree – a clear goal for future studies will be to directly test the role of MEKK1 and MAP2K4 <italic>loss-of-function</italic> mutations in breast cancer. We have revised the Discussion to state this important point.</p><disp-quote content-type="editor-comment"><p>8) At several places in the manuscript (Introduction and Conclusion) the authors state that their discovery that loss of JNK1/2 expression promotes breast cancer may 'present an opportunity for therapeutic intervention'. It is not immediately obvious how a small molecule could rescue the effects of losing JNK1/2 expression to prevent genome instability. Presumably they are thinking about a disease stratification approach in which those breast cancers with loss of function mutations on the JNK pathway and enhanced genome stability may be more susceptible to intervention with drugs targeting DNA Damage Response (DDR) pathways, analogous to synthetic lethality that has helped to drive approval of PARPi? Or do they envisage combination of JNKi and DDRi as being synthetic lethal in cells that do not have JNK pathway mutations? A little more information here, or discussion, would help to clarify ideas and potential significance for the reader.</p></disp-quote><p>We agree that the conclusions on this point were not stated clearly in the original version of our manuscript. Our expectation is that <italic>JNK</italic>-deficiency would exhibit synthetic lethality with drugs that cause DNA damage or prevent DNA repair. We have revised the Discussion to state this more clearly.</p><disp-quote content-type="editor-comment"><p>9) In Figure 3 and Figure 3—figure supplement 2 the authors describe how the <underline>Kras</underline> locus is more frequently amplified in JNK<sup>WT</sup> mice compared to JNK<sup>KO</sup>. Could the authors comment on the significance of this observation? Are they proposing that because the JNK<sup>KO</sup> tumours display increased genome instability they are likely to acquire many more oncogenic events and thus become less reliant on the amplification of the Kras locus which is prevalent in the JNK<sup>WT</sup> mice?</p></disp-quote><p>We agree that our conclusions were not clearly stated in the original manuscript. As stated by the reviewers, we suspect that the <italic>Kras</italic> amplification detected in WT tumors was functionally substituted by the mutation of other oncogenic pathways in the <italic>JNK</italic> knockout tumors. We have revised the last paragraph of the subsection “JNK deficiency rapidly accelerates tumor development in a mouse model of breast cancer” to state this more clearly and by including gene set enrichment analysis for a <italic>Kras</italic> signaling signature (Figure 3—figure supplement 3).</p></body></sub-article></article>